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Breast cancer is the most common type of cancer among woman all over the world, with 
over 1.67 million new cases in 2012. Heritable breast cancer is closely linked to mutations 
in the tumor suppressor gene BRCA1, with up to 80% lifetime risk for developing breast 
cancer among women harboring a mutation in this gene. However, most breast cancer cases 
are sporadic and somatic mutations of the BRCA1 gene are rare. Furthermore, some tumors 
show BRCAness, despite being BRCA1 wild-type. Thus, it is of great interest to assess 
alternative mechanisms for inactivation of the BRCA1 gene, and addressing the missing 
causality of many breast cancers. Furthermore, it is of great interest to assess the 
mechanisms of drug resistance, a major challenge in cancer treatment today, where BRCA1 
may play an important role.  
 
The overall aim of this thesis is to increase the understanding of the biological role of 
BRCA1 promoter methylation in breast cancer. Three sub aims for the present project were 
outlined; 1) Quantify the BRCA1 a and b transcripts and the total BRCA1 protein levels 
and relate the expression data to the methylation pattern in the BRCA1 promoter region in 
a panel of breast cancer cell lines. 2) Investigate how the total expression levels, as well as 
the ratio between the a and b transcripts are affected by alterations in the a and b promoter 
region of BRCA1, including methylation of specific CpGs as well as the polymorphisms 
rs71361504 and rs799905. 3) Investigate the effect of long term treatment with the drugs 
olaparib and doxorubicin on the BRCA1 promoter methylation in SKBR3 breast cancer 
cells as a potential cause of drug resistance. 
 
The study showed a weak correlation between BRCA1 methylation pattern and BRCA1 
mRNA expression. No correlation was observed between the methylation pattern and 
protein expressed or between mRNA levels and protein expression. Analysis of 
polymorphisms rs71361504 and rs799905 found in the BRCA1 promoter showed that the 
two variants seemed to counter-balance each other, giving equal luciferase expression 
levels when differing in two positions and lower expression levels when intermediate 
variants were studied. Finally, long term drug treatment of the cell line SKBR3 did not 
alter the methylation levels in the BRCA1 promoter, consequently demethylation seems not 





Cancer is a major global health problem. In 2012, 8.2 million people died of cancer 
(mortality), 14.1 million new cancer cases were reported (incidence), and 32.6 million 
people were living with cancer (prevalence) worldwide (IARC, 2012). In Norway, a 
total of 32 592 new cancer cases were diagnosed in 2015 (Kreftregisteret.no, 2017). 
 
Cancer is a group of diseases characterized by uncontrolled cell growth. A cancer cell 
evolves in a progressive manner, gradually acquiring properties necessary for 
neoplastic development. The cancer specific properties have, for simplicity, been 
classified into ten different “hallmarks” of cancer (Figure 1.1) (Hanahan and Weinberg, 
2000, Hanahan and Weinberg, 2011) These hallmarks of cancer include genomic 
instability and mutation, tumor promoting inflammation, production of signals that 
sustain proliferation and evade growth repression. Further, a developing cancer cell 
needs to escape programmed cell death and enable replicative immortality, as well as 
induce angiogenesis, activate invasion and metastasis, deregulate cellular energetics 
and avoid immune destruction.  
 
Cancer is regarded as a genetic disease at the cellular level caused by accumulation of 
genetic and epigenetic alterations providing growth advantages over neighboring cells. 
The development of cancer is largely governed by the functions of tumor suppressor 
genes and proto-oncogenes. Tumor suppressor genes protect cells from transforming 
into malignant cancer cells while proto-oncogenes can potentially induce cancer 
(become oncogenes) if hyper-activated. Alterations that inactivate a tumor suppressor 
gene, or activate or amplify a proto-oncogene, can contribute to malignant 
transformation of cells. Such alterations, directly contributing to cancer development 
and growth, are called “drivers”, while the majority of alterations found in cancer cells 
are “passengers”, not contributing to cancer development (Stratton et al., 2009, 
Greenman et al., 2007, Sjoblom et al., 2006).   
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Figure 1.1: The hallmarks of cancer are ten properties characterizing cancer cells as described by 
Hanahan and Weinberg in 2000 and 2011. The properties are acquired in a progressive matter, by 
genetic and/or epigenetic changes in the DNA. Modified from (Hanahan and Weinberg, 2000, Hanahan 
and Weinberg, 2011).  
 
1.2 Breast cancer 
Among all cancer forms, breast cancer is the second most common and the most 
common for women. In 2012, 1.67 million new cases of breast cancer were diagnosed 
worldwide (IARC, 2012). In Norway, 3439 new cases of breast cancer were registered 
in 2015, making up >10% of all new cancer diagnosis that year (Kreftregisteret.no, 
2017). The breast cancer prevalence is increasing in developed countries, owing to both 
increased incidence (linked to western lifestyle) as well as improved screening 
programs/early detection (Ma and Jemal, 2013, Desantis et al., 2016, Senkus et al., 
2013). However, breast cancer is still the leading cause of cancer-related deaths among 
European women (Senkus et al., 2013). 
 
1.2.1 Breast cancer classification 
Over the last decades, it has become evident that breast cancer is not a single disease, 
but rather a diagnosis that can be divided into many subclasses. The most common 
stratifications are to subgroup breast cancers according to their hormonal receptor 
status, that is, whether they express receptors for estrogen (ER) and/or progesterone 
PR). Further, an important stratification parameter (for treatment choice) is whether the 
tumor cells overexpress the Her2 receptor (see section 1.2.1). Breast cancers may also 
be divided according to histological type, with the two main forms being ductal and 
lobular carcinomas. Based on gene expression profiles, breast cancers have also been 
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divided into five subtypes with specific phenotypes and clinical outcomes; Luminal A, 
Luminal B, Her2 over-expression, Basal-like, and Normal-like. Luminal A is predicted 
to have the best survival outcomes, while Basal-like, which often include a triple 
negative receptor status (ER, PR, Her2), is associated with the poorest disease 
prognosis (Sorlie et al., 2003, Sorlie et al., 2001, van 't Veer et al., 2002, van de Vijver 
et al., 2002, Perou et al., 2000).   
 
1.2.2 Factors contributing to breast cancer development 
Cancer is induced by multiple factors, but the exact cause is not fully understood. 
However, it is well established that the risk of breast cancer is influenced both by 
environmental and genetic factors. Some of the most important environmental factors 
linked to breast cancer risk are age, reproductive and hormonal aspects, diet/obesity, 
lack of physical exercise, alcohol consumption and exposure to X- and g-radiation 
(Stewart, 2014). Many of these factors are associated with the western life style (Buell, 
1973), and the western part of the world is also where the breast cancer incidence is the 
highest (IARC, 2012).  
 
While most breast cancer cases are considered to be sporadic (i.e not caused by high 
risk genetic factors), a small fraction (1-5%) of all breast cancers (Davies et al., 2017) 
(2% in Norway (kreftforeningen.no)) are linked to inherited genetic variants 
predisposing to high risk of breast cancer. The best example is germ line mutations in 
the BRCA1 gene that predispose women to breast as well as ovarian cancer (Rohini et 
al., 2011). Women harboring mutations in BRCA1 have a lifetime risk of 50-80% for 
developing breast cancer and 30-50% for ovarian cancer (Rahman and Stratton, 1998, 
Antoniou et al., 2003). Other genes in which germline mutations are associated with 
risk of breast cancer, are TP53, CHEK2, PTEN and more. 
 
1.2.3 Breast cancer treatment 
Breast cancer treatment options include surgery, chemotherapy, radiation, endocrine 
therapy, and targeted therapy. Recently, immunotherapies have also been applied in 
clinical trials (Ling et al., 2017, Curigliano et al., 2016). Several factors affect the 
choice of treatment such as tumor stage/grade, lymph node and hormonal receptor 
status, Her2-status, age (menopausal status) and patient’s health and own preference 
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(Senkus et al., 2013). In recent clinical trials regarding sporadic cancers, mutation status 
of specific genes (such as TP53) is also included as a parameter for treatment choice. 
Most breast cancers are treated with surgery followed by radiation. Chemotherapy is 
generally used as adjuvant therapy and in relation to metastasis and relapse, as well as 
for patients that for various reasons cannot go through surgery. For large tumors, 
chemotherapy is also used prior to surgery (neo-adjuvant treatment) 
(kreftforeningen.no).  
 
Doxorubicin is a classical chemotherapeutic drug used in breast cancer as well as many 
other cancer forms. Doxorubicin is an anthracycline with cytotoxic mechanisms 
involving DNA intercalation, topoisomerase inhibition and generation of free oxygen 
species, resulting double stranded breaks (DSB). This, in turn, leads to cell cycle arrest, 
senescence or apoptosis (Niethammer and Bruchelt, 1998).  
 
Poly ADP ribose polymerase (PARP) inhibitor, is a newer and more targeted therapy 
which is given to patients with a BRCA1 mutation (Rafii et al., 2017) and has also been 
suggested to patients displaying other types of BRCA1 deficiency, including 
hypermethylation in the BRCA1 promoter (Veeck et al., 2010). PARP is a group of 
proteins involved in single stranded DNA repair trough base-excision repair. If the 
PARP-protein is inhibited, single stranded breaks will eventually turn into double 
stranded (ds) breaks. In normal cells, ds DNA breaks (DSB) are repaired by 
mechanisms including BRCA1 dependent homologous recombination (HR) repair. 
Hoewever, when treating BRCA1/2-mutated and potentially methylated cells displaying 
deficient DSB repair system with PARP-inhibitor (PARPi), this will not happen and 
the targeted cell will die (figure 1.2) (Fong et al., 2010). This treatment model utilizes 
a defect already present in the cell as an advantage for selectively killing the cancer 
cells, a concept termed synthetic lethality. Olaparib is an example of a promising 
PARP-inhibitor, and several clinical trials are testing the effect of this drug (Murata et 








Figure 1.2: Overview of the role of PARP1 and BRCA1/2 in synthetic lethality. DNA damage can 
be repaired by several mechanisms involving different molecules, normal cells should have both base-
excision repair and homologous recombination (A). DNA can still be repaired by base-excision repair if 
BRCA is mutated (B), and by homologous recombination if PARP1 is inhibited (C). A cancer cell can 
be targeted by synthetic lethality when BRCA mutated cells are treated with PARP1 inhibitor, and when 
neither base-excision repair, nor homologous recombination can be performed, the DNA will not be 
repaired and the cell will die (D). Reproduced with permission from (Iglehart and Silver, 2009), 
Copyright Massachusetts Medical Society. 
 
Despite many efficient treatment options, there are still major challenges in current 
breast cancer management. One such challenge is the development of drug resistance, 
which is the main cause of unsuccessful treatment and subsequent death (Foo and 
Michor, 2009, Lonning and Knappskog, 2013). In order to improve treatment results, a 
deeper understanding of the underlying mechanisms and pathways for development of 
treatment resistance within the cancer cell is needed. Both genetic and epigenetic 
processes should to be considered, however, epigenetics is of particular interest due to 
its highly dynamic nature.  
 
1.3 Breast cancer gene 1 
Breast cancer susceptibility gene 1 (BRCA1) was identified in 1990 and isolated and 
cloned in 1994 (Miki et al., 1994, Hall et al., 1990). The BRCA1 gene is located on 
chromosome 17q21.3, consists of 23 coding exons and encodes a large protein of 220 
kDa, consisting of 1863 amino acids (figure 1.3). The BRCA1 gene is partially 
duplicated, resulting in a pseudo BRCA1 gene containing only exon 1A, 1B and 2. 
Pseudo BRCA1 is located of the same chromosomal band, separated from the wild-type 
BRCA1 by the NBR2 gene (figure 1.3 A). Notably, the pseudo BRCA1 gene has also 
been found to be expressed in malignant cells (Pettigrew et al., 2010). 
 
	 6	
1.3.1 BRCA1 protein domains and function 
The BRCA1 protein contains several functional domains including a N-terminal RING 
domain involved in heterodimerization of BRCA1/BARD1, providing E3 ubiquitin 
ligase activity. Two nuclear localization sequences (NLS) are located towards the N 
terminus, allocating BRCA1 to the nucleus. A coiled-coil domain found towards the C-
terminus of the protein is involved in binding to Partner and localizer of BRCA2 
(PALB2). Two BRCA1 C-terminal (BRCT) domains that bind proteins involved in 
transcription and DNA damage response (Rohini et al., 2011, De Siervi et al., 2010) are 
also located in the C-terminal end (figure 1.3 B). The central region of BRCA1 does 
not contain any known functional domains, which allows for a wide array of structural 
changes and the possibility to bind a range of other molecules (Savage and Harkin, 
2015). BRCA1 phosphorylation is involved in subcellular localization of the protein 
(Scully and Livingston, 2000, Scully et al., 1997, Brodie and Henderson, 2010). 
Through its protein domains, BRCA1 interact with a myriad of other proteins resulting 
in numerous large protein complexes which participates in several important processes 
including cell cycle regulation, regulating of transcription, ubiquitination, chromatin 
remodeling, mRNA splicing, apoptosis, maintenance of genome integrity and repair of 
dsDNA breaks through homologous recombination (HR) (Savage and Harkin, 2015), 
the latter being among the most relevant function with respect to BRCA1 tumor 
suppressor activities.  
 
 
Figure 1.3: Schematic presentation of BRCA1 gene localization and functional domains of BRCA1 
protein. A) The y-BRCA1 is located upstream to BRCA1 on the negative strand in the human genome. 
NBR2 is located between the two genes and is transcribed in the positive direction. B) Protein domains 
and binding partners for the BRCA1 protein.  
 
DSB is considered to be one of the most hazardous types of DNA damage, and can be 
repaired trough two major pathways called homologous recombination (HR) and non-
homologous end joining (NHEJ). It is well established that BRCA1 plays a central role 
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in HR as illustrated in figure 1.4 (Rohini et al., 2011). DSB are detected by sensor 
molecules, which signal mediators that in turn can activate effectors and allowing repair 
of the damage. BRCA1 is considered a mediator; it binds to several other proteins and 
allow recruitment of molecules involved in HR. One of the first responses to DSB is 
phosphorylation of histone H2A.X, which starts a cascade of reactions leading to 
binding of complex abraxas-RAP80 and promotion of BRCA1. BRCA1 is important 
for recruiting a myriad of molecules and complexes involved in DSB-repair, as well as 
in strand resection by interactions with CtIP and MRN (MRE11-RAD50-NBS1). 
Furthermore, BRCA1 interacts with PALB2 and BRCA2 which lead to RAD51 
mediated HR by invasion of sister chromatid. DNA is synthesized by a DNA 
polymerase and the strands can be relegated. The BRCA1-BRIP1-TOPBP1 complex is 
associated with DNA repair, but the exact mechanisms are unknown (Savage and 
Harkin, 2015, Ronit et al., 2002, Rohini et al., 2011) (figure 1.4).  
 
Figure 1.4: The role of BRCA1 in homologous recombination (HR). BRCA1 is involved in double-
stranded break (DSB) repair. DSB are detected by sensors (light blue) which lead to a cascade of 
reactions and the recruitment of BRCA1, which is considered a mediator (dark blue). BRCA1 is involved 
in recruiting molecules, involved in HR repair. BRCA1 bound to relevant complexes, is involved in both 
resection and strand invasion by binding to various effectors (turquoise). Reproduced with permission 
from (Rohini et al., 2011), Copyright Nature Publishing Group.  
 
1.3.2 The BRCA1 promoter region 
BRCA1 transcription is under regulation of two promoters; a and b, which generate two 
different transcripts containing either exon 1a or exon 1b, respectively (Xu et al., 1995, 
Xu et al., 1997). The two BRCA1 transcripts (called BRCA1 a and b transcript) differ 
in length and nucleotide sequence, but the protein products arising from the transcripts 
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are identical independent on whether the transcript contains exon 1a or exon 1b as the 
start codon for translation is located in exon 2. Promoter a, consisting of just over 200 
bp, spans a slightly larger region than promoter b, which consist of approximately 150 
bp. 
 
The BRCA1 promoter does not contain a classical TATA box, however, several 
transcription factor binding sites associated with TATA-less promoters are found in the 
BRCA1 promoter region. Transcription factor binding sites for specific protein 1 (Sp1), 
the cyclic AMP responsive element binding (CREB) protein (Hockings et al., 2008, 
Mancini et al., 1998), RIBS element, E2F transcriptions factor family and more 
(Mueller and Roskelley, 2003, Xu et al., 1995). BRCA1 is also found to be regulated by 
estrogen (E2) through a non-classic activation pathway. BRCA1 lacks the classic E2-
response elements, but E2-liganded-ERa can bind to the p300 co-activator, which can 
interact with Jun/Fos transcription factors which bind to a AP-1 site located in the 
BRCA1 promoter (Shukrun et al., 2014, Jeffy et al., 2005, Xu et al., 1997).  
 
Interestingly, the BRCA1 a transcript is found to be expressed in both normal and 
cancerous breast tissue, while the BRCA1 b transcript is only found to be expressed in 
breast cancer tissue (Xu et al., 1995, Sobczak and Krzyzosiak, 2002). These findings 
indicate that at some point during neoplastic development, BRCA1 transcription is 
deregulated, resulting in the activation of promotor b. Altered dynamics of methylation 
of CpG dinucleotides located in the promotor region of BRCA1 could potentially be 
among the mechanisms involved in the switch from a to b promoter. Altered dynamics 
of methylation of CpG dinucleotides located in the promotor region of BRCA1 could 
potentially be among the mechanisms involved in the switch from a to b promoter. 
Furthermore, the expression of BRCA1 a transcript has been found to be 6-150 times 
higher than the BRCA1 b transcript (Fernandes et al., 2014, Xu et al., 1997), where 
possible explanations could be regulation by different transcription factors. In addition, 
translation of the BRCA1 WT b transcript has also been shown to be less efficient, 
suggested explanations involve alternative and suboptimal start codons that allow 
premature initiation and termination, stable secondary structures within the b transcript 
which interfere with assembly of pre-initiation complex and 40S ribosomal subunit 
scanning of mRNA (Sobczak and Krzyzosiak, 2002). 
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1.3.3 BRCA1 alterations in breast cancer 
The BRCA1 gene is closely linked to cancer, due to the very high risk of female cancers 
including breast and ovarian cancer, among carriers of germline mutations. Of a total 
of 1277 entries in the BRCA1 Database provided by The University of Utah, most of 
the germline mutation variants that are observed for BRCA1 are deletions (43%), 
followed by nonsense mutations (20%) and insertions (15%) among other 
(www.arup.utah.edu, 2017).  
 
Regarding somatic mutations, a total of 548 unique cancer samples are registered with 
BRCA1 mutations, in the catalogue of somatic mutation in cancer database (COSMIC 
v.81) (Forbes et al., 2017). The most common somatic alteration of BRCA1 gene in 
cancer is missense substitutions (60%), synonymous mutations (17%) and nonsense 
mutations (10%). Copy number variation (CNV), large genomic rearrangements (LGR) 
and loss of heterozygosity (LOH) are genetic alterations that also are observed in 
BRCA1 cancers (Ewald et al., 2009, Fridlyand et al., 2006, Hampton et al., 1994). Other 
mutations detected include frameshift insertion and deletion, in-frame deletion and 
more. However, somatic mutations of BRCA1 in sporadic breast cancer are rare 
(Catteau and Morris, 2002), yet decreased expression of BRCA1 mRNA and protein is 
still observed in breast tumors despite the absence of mutations of the BRCA1 gene 
(Thompson et al., 1995, Hasan et al., 2013). In addition, cancers might have global 
mutational profiles reflecting deficient HR repair even if they do not harbor mutations 
in BRCA1. This phenomenon is termed “BRCAness” and is defined by “traits that some 
sporadic cancers share with those occurring in either BRCA1 or BRCA2-mutation 
carriers” (Davies et al., 2017, Turner et al., 2004). This indicates that mechanisms other 
than mutations must be involved to cause inactivation or down-regulation of BRCA1. 
DNA methylation in the promoter region is proposed as such an alternative mechanism 
for silencing of tumor suppressor genes (Rice et al., 1998), potentially explaining some 
of the missing causality of breast cancer.  
 
1.4 Epigenetics and DNA methylation 
“The term epigenetic includes regulatory mechanisms that influence gene expression 
without any changes in the sequence of the DNA” (Gaal and Olah, 2014). Epigenetic 
	 10	
changes have the potential to alter gene expression through several mechanisms; the 
main mechanisms include DNA methylation and covalent tail modifications of histones 
(mostly methylation and acetylation). DNA methylation is the most studied epigenetic 
modifications in the human DNA. It involves covalent binding of a methyl group (-
CH3) to the 5-position of the pyrimidine ring of a cysteine (C) nucleotide in primarily 
CpG dinucleotides (where p stands for the phosphate bond between the nucleotides), 
resulting in 5-methylcytosine (m5C). The reaction adding methyl to DNA is catalyzed 
by the DNA methyl transferase (DNMT) enzyme family (figure 1.5).  
 
Figure: 1.5: Methylation of cysteine by metyltransferase. Methylation of the cytosine pyrimidine ring 
catalyzed by the enzyme methyltransferase.  
 
Methylation of CpGs has been found to be the most common form of methylation in 
humans. Approximately 50% of the human genes contain short stretched with high 
content of CpG dinucleotides termed CpG islands (CGI), these are usually located in 
promoters, while the rest of the genome is generally depleted of CpGs (Jones, 2012). 
Hyper- or hypomethylation of a promoter region can be involved in transcriptional 
silencing or activation of a gene, respectively. Genes that are transcribed in a normal 
manner generally have unmethylated promoter regions. (Ali et al., 2011, Kloten et al., 
2013). Methylation in the promoter region can lead to silencing of genes by several 
mechanisms. One of the mechanisms involves direct blocking of transcription factor 
binding sites by methylation within or close to these sites. A second model proposes 
that methylation attracts proteins that specifically bind and consequently block the 
access of other factors required for gene expression. Additionally, DNA methylation 
can be involved in compact packing of chromatin resulting in inactive regions 
(heterochromatin). 
 
While methylation in promoter regions are associated with silencing of genes, 
methylation of the gene body is associated with actively transcribed genes (Wolf et al., 
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1984). Most gene bodies have only a few CpGs, but these are generally methylated. 
Methylation is known to be involved in several processes like embryonic development 
(Li et al., 1992), imprinting (Wolf et al., 1987) and X chromosome inactivation (Riggs, 
1975) as well as and regulation of diseases, including cancer (Vardhman et al., 2011, 
Haoyang, 2013, Nguyen et al., 2010, Kulis and Esteller, 2010) 
 
1.4.1 The role of DNA methylation in cancer 
Abnormalities like loss and gain of methylation, hypo- and hypermethylation, 
respectively, are widely associated with cancer development. A global reduction of 
methylation, along with hypermethylation of the promoter of tumor suppressor genes 
are phenomena commonly observed in cancer (Gama-Sosa et al., 1983, Eden et al., 
2003). Genome wide demethylation can lead to chromosome instability due to 
activation of transposable elements/reteroviral elements (Hansmann et al., 2012) and 
recent sequencing efforts have revealed a large number of structural rearrangements, 
(involving genes, exons and regulatory elements) in cancer genomes to be associated 
with, and possibly caused by, re-activated retroviral elements (Tubio et al., 2014). 
Aberrant hypermethylation in the promoter region is among the most common way of 
silencing of tumor suppressor genes and represent an alternative inactivating 
mechanism to mutations. Aberrant hypermethylation in the promoter region has been 
described for several tumor suppressor genes in breast cancer including CDH1, 
RASSF1A and BRCA1 (Cho et al., 2010). Cytosine methylation status can also affect 
cancer by oncogenic point mutations due to spontaneous deamination of methylated 
cysteines. The focus in this thesis is on methylation in the promoter of BRCA1.  
 
1.4.2 Aberrant methylation of BRCA1 promoter in breast cancer 
The tumor suppressor gene BRCA1 can be epigenetically silenced by hypermethylation 
within the promoter (Esteller et al., 2000, Esteller et al., 2001, Hasan et al., 2013) and 
experimental demethylation of BRCA1 leads to reactivation of the gene (Choudhury et 
al., 2016). Furthermore, significantly higher levels of methylation among CpGs in the 
BRCA1promoter have been found in breast cancer compared to normal tissue (Zhang 
and Long, 2015, Ali et al., 2011). Hypermethylation of the BRCA1 promoter is found 
in approximately 5-65% of sporadic breast cancers (Ignatov et al., 2013, Buyru et al., 
2009, Birgisdottir et al., 2006). The range in frequency might be explained by factors 
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including methylation detection method, CpGs/area analyzed and potential 
contamination by unmethylated normal tissue. Some studies have analyzed the 
methylation pattern of individual CpGs in the BRCA1 promoter region of breast cancer 
and ovarian cancer, revealing the methylation pattern to be highly heterogeneous (Rice 
et al., 2000, Wilcox et al., 2005, Scott et al., 2016, Hansmann et al., 2012).  
 
In patients carrying BRCA1 germline mutations, it is believed that a “second hit” is 
needed for inactivation of the wild-type BRCA1 allele and for development of cancer 
(Birgisdottir et al., 2006, Chenevix-Trench et al., 2006). Some studies have proposed 
that methylation of BRCA1 promoter may serve as this second hit in tumors of such 
patients (Tapia et al., 2008, Esteller et al., 2001). Phenotypically, BRCA1-methylated 
tumors are similar to those occurring in carriers of germline BRCA1 mutations, thus 
displaying “BRCAness”. BRCA1 promoter methylation in breast cancer patients has 
been found to correlate with reduced expression levels of both mRNA (Galizia et al., 
2010, Rice et al., 2000, Hasan et al., 2013) and protein (Scott et al., 2016, Wu et al., 
2016), confirming aberrant promoter methylation to be an important inactivating 
mechanism. Furthermore, BRCA1 promoter methylation is suggested to be involved in 
initiation of tumor development, and that it could be used as a biomarker for early 
detection of sporadic breast cancer (Hosny et al., 2016, Ali et al., 2011, Cho et al., 2010, 
Hansmann et al., 2012).  
 
Recent meta-analyses reported BRCA1 promoter methylation to be associated with 
various clinico-pathological features such as lymph node metastasis, histological grade 
3, triple-negative phenotype as well poor survival of patients with breast cancer (Zhang 
and Long, 2015, Wu et al., 2013, Birgisdottir et al., 2006). These findings indicate that 
hypermethylation of the BRCA1 gene promoter could be an important marker for 
prognosis.  
 
Triple negative breast cancer (negative for ER, PR and Her2) is an aggressive subtype 
which is difficult to treat and often associated with loss of function of the BRCA1 gene, 
either through mutation, loss of heterozygosity, or methylation (Lips et al., 2013). 
Identification of predictive markers involved in this type of cancer is crucial to improve 
breast cancer survival. Several studies have suggested that tumors with BRCA1 
promoter methylation have features similar to those harboring BRCA1 mutations, and 
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therefore may be suitable for the same targeted therapies, such as platinum based 
chemotherapy agents and PARP-inhibitors. Consequently, methylation status could be 
used as a biomarker for treatment strategy decisions (Sharma et al., 2014, Veeck et al., 
2010).  
 
1.4.3 Methods for detection of methylation 
Numerous methodological approaches exist for detecting DNA methylation including 
methylation-sensitive restriction enzymes (MSREs), methylation-specific PCR 
(MSP/USP PCR), pyrosequencing and methylation specific next generation sequencing 
(NGS) (Delpu et al., 2013). MSREs was one of the first methods used, and this method 
allowed identification of exact CpG position within the DNA, however, detected CpGs 
are limited to restriction sites in the given region. 
 
A number of the methods for analyzing DNA methylation utilize bisulfite converted 
DNA as starting material. Methylation involves binding of a chemical group to DNA, 
and does not induce a change within the DNA backbone, consequently ordinary 
sequencing cannot detect methylation. Bisulfite conversion offers a solution to the 
problem of detection. When treating DNA with sodium bisulfite, methylated cytosine 
nucleotides are left unchanged, while unmethylated cytosine are chemically 
deaminated, thus turning unmethylated Cs into uracil, which then can be detected as 
thymine after PCR (figure 1.6) (Frommer et al., 1992) (Hayatsu, 2008, Wang et al., 
1980). In this way, a previously undetectable epigenetic marker/chemical tag is turned 
into change in the nucleotide sequence detectable by sequencing.  
 
Figure 1.6: Bisulfite conversion of methylated and unmethylated CpG’s. When treated with sodium 
bisulfite, methylated Cs remain unchanged while unmethylated Cs are deaminated to Us, which can be 
detected as Ts after PCR and sequencing. 
 
MSP/USP PCR, utilize bisulfite converted DNA and is an easy and low cost PCR based 
method dependent on 5-10 CpGs covered by the primers. A drawback with the method 
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is that methylation status can only be collected for the area covered by the primers. In 
addition, due to the need for separate assays for methylated versus unmethylated 
specific amplifications, assessment of the methylation ratio is challenging. 
Pyrosequencing is a technique that also utilize bisulfite converted DNA, it is rapid and 
can be standardized.  Even if qPCR is more sensitive, this method has most of the same 
drawbacks as MSP/USP PCR. However, many labs currently use pyrosequencing as 
the standard for quantification of DNA methylation, but improved NGS methylation 
protocols are being developed.  
 
NGS methods give the best coverage of CpGs and read depth, but the methods are still 
rather expensive and demand advanced bioinformatical processing of data. The Roche 
NimbleGen protocol SeqCap Epi Target Enrichment of bisulfite treated DNA allows 
methylation assessment at single-base resolution for all possible methylation 
combinations on both strands. However, in the context of NGS and methylation, 
mapping is extra challenging because one region could be fully methylated, partly 
methylated or unmethylated. In addition, due to bisulphite conversion the upper and 
lower strand are no longer complementary, and the genome is doubled. Another 
challenge is polymorphic variants in CpG positions, which is important to identify 
because true C that have been changed to T in the evolution cannot be separated from 
C to T substitutions caused by bisulfite conversion. These positions might thus be 
mistakenly interpreted as unmethylated C’s. NGS data can be analyzed in context of 
SNPs by algorithms that uses known SNPs in the genome and comparison of the 
obtained reads. The output NGS data also allow calculation of percentage methylation 
at individual CpG and in specific regions of interest.  
 
It is likely that methods for analysis of DNA methylation will be improved in the near 
future. Although still hampered by a high error-rate, one of the most promising 
approaches is to apply nanopore sequencing capable of distinguishing five different 
bases in a DNA strand (A, G, T, C and mC), thereby merging genetic and epigenetic 
analyses into a single experiment, without prior bisulfite conversion of DNA (Simpson 






Based on the given background knowledge, and the overall aim to increase the 
knowledge of the biological role of BRCA1 promoter methylation, the three sub aims 
of this master thesis are: 
 
1. Quantify the BRCA1 a and b transcripts and the total BRCA1 protein levels and 
relate the expression data to the methylation pattern in the BRCA1 promoter 
region in a panel of breast cancer cell lines. 
 
2. Investigate how the total expression levels, as well as the ratio between the a 
and b transcripts is affected by alterations in the a and b promoter region of 
BRCA1, including methylation of specific CpGs as well as polymorphisms 
rs71361504 and rs799905.  
 
3. Investigate the effect of long term drug treatment with drugs olaparib and 



















3.1 Cell culturing 
 Table 3.1.1: Cell lines with description of tissue, sub-class and receptor status* 
Cell line  ATCC® ID Tissue Sub-class Receptor status 
SKBR3  ATCC HTB-30 breast  Her2 over express ER-, PR-, Her+ 
ZR-75-1 ATCC CRL-1500 breast (metastatic) Luminal B ER+, PR+, Her+ 
UACC-3199 ATCC CRL-2983 breast (metastatic) Unknown ER-, PR-, Her+ 
BT-549 ATCC HTB-122 breast  Basal like  ER-, PR-, Her- 
T-47D ATCC HTB-133 breast (metastatic) Luminal A ER+, PR+, Her- 
HCC38 ATCC CRL-2314 breast Unknown ER-, PR-, Her- 
MCF7 ATCC HTB-22 breast (metastatic) Luminal A ER+, PR+, Her-  
MDA-MB 231 ATCC HTB-26 breast (metastatic) Basal-like  ER-, PR-, Her- 
MDA-MB 468 ATCC HTB-132 breast (metastatic) Basal like ER-, PR-, Her- 
*Sub-class and receptor status retrieved from ATCC and article “Choosing the right cell line for breast 
cancer research” (Holliday and Speirs, 2011).  
 
Table 3.1.2: Cell lines and corresponding medium reagents 










SKBR3 McCoy’s 5a  10% - - 
ZR-75-1 RPMI-1640  10% 4 mM - 
UACC-3199 Leibovitz’s L-15  
 
5% 2 mM 0.01 mg/mL transferrin  
0.01 mg/mL insulin  
5 µg/mL catalase  
3.6 µg/mL hydrocortisone  
BT-549 RPMI-1640  10% 4 mM 0.023 U/mL bovine insulin  
T-47D RPMI-1640  10% 4 mM 0.2 U/mL bovine insulin  
HCC38 RPMI-1640  10% 4 mM - 
MCF7 EMEM 10% 4 mM - 
MDA-MB 231 RPMI-1640  10% 4 mM  - 
MDA-MB 468 Leibovitz’s L-15  10% 4 mM Cultured without CO2 
* All media were prepared with 5% PenStrep (Life technologies, 15070-063). When required, cells were 
split with trypsin-EDTA (Lonza17-516F).  
 
Table 3.1.3: Drugs for cell treatment 
Name  Supplier (Cat #) 
DMSO Sigma Aldrich (D2650) 
Olaparib  Selleckchem (S1060) 
Doxorubicin Nycomed pharma (417154) 
 
3.2 Transfection 
Table 3.2.1: Plasmids and transfection reagents 
Name Supplier (Cat #) 
OPTI-MEM® Life Technologies (31985062) 
Lipofectamine LTX Reagent and PLUS reagent Invitrogen (15338100) 
pGL4.10[luc2] Vector Promega (E665A) 
pGL4.13[luc2/SV40]  Promega (E6681) 
pCMVcytoEGFP In house  




Table 3.3.1: Reagents and kits used for bacterial transformation and cloning  
Name Supplier (Cat #) 
TOPO TA Cloning kit including: 
- One Shot Top 10 cells (E. coli*) 
- pCR2.1-TOPO vector 
Invitrogen, Life technologies (K4500-40) 
 
S.O.C Medium Invitrogen (15544-034) 
Ampicillin Bristol-Myer Squibb (056432) 
X-Gal Sigma Aldrich (B4252) 
1x CutSmart NEB Buffer  New England BioLabs (B72045) 
KpnI-HF  New England BioLabs (R3142) 
HindIII-HF  New England BioLabs (R3104) 
T4 DNA Ligase TaKaRa (2011A) 
10x T4 DNA ligase buffer  TaKaRa (2011A) 
Shrimp Alkaline Phorphatase (rSAP) New England BioLabs (M0371S) 
*E.coli species: F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara leu) 
7697 galU galK rpsL (StrR) endA1 nupG 
 
3.4 DNA, RNA and protein extraction and purification 
Table 3.4.1 Reagents and kits used for DNA, RNA and protein extraction 
Name Sample  Supplier (Cat #) 
QIAmp DNA Mini Kit DNA Qiagen (51306) 
TRIzol Reagent RNA Life Technologies (15596-018) 
Chloroform RNA VWR (97064-678)  
Isopropanol RNA Sigma Aldrich (I9516) 
Protein lysis buffer 
- 50 mM Tris-HCl (pH 7.5) 
- 150 mM NaCl 
- 0.1% SDS 
- 1% Deoxycholate 
- 1% Triton X-100  
To 10 ml of Protein lysis buffer added: 
- ULSTRA, Mini, Protease Inhibitor Cocktail 
Tablet  
- PhosSTOP Phosphate Inhibitor Cocktail tablet  










QIAprep Spin, mini-prep kit Plasmid Qiagen (27016) 
Illustra GFX PCR DNA and Gel Band Purification kit DNA GE Healthcare (28-9034-70) 
HiSpeed Plasmid Purification MaxiPrep DNA Qiagen (21663) 
 
3.5 DNA bisulfite conversion 
Table 3.5.1 Kit and controls used in bisulfite conversion of DNA 
Name Supplier (Cat #) 
EZ DNA Methylation-Gold Kit Zymo Research (D5005) 
Cp Genome Universal Methylated DNA (pos. 
control) 
Millipore (S7821) 







3.6 PCR systems 
Table 3.6.1: Polymerases and buffer components 
Name Supplier (Cat #) 
AmpliTaq Gold polymerase Kit Applied Biosystems (4311820) 
2 mM dNTP TaKaRa (4026, 4027, 4028, 4029) 
VWR Taq DNA polymerase Kit VWR (5101600-0100) 
10 mM dNTP TaKaRa (4026, 4027, 4028, 4029) 
DNA template (purified from pooled blood 
samples from five health individuals) 
Gift from by Elisabet Ognedal Berge, Mohn lab 
DyNAzymes EXT  BioRad (172-5300) 
LightCycler 480 Probes Master  Roche (04887301001) 
 
3.7 Primers 
Table 3.7.1 Primers* used for PCR amplification and Sanger sequencing 
Name  Direction Sequence (5’à3’)  Annealing temp (°C) 
Primers used for PCR amplification of BRCA1 promoter from bisulfite converted DNA (cell lines) 
for TA cloning   
CpG Island F1 F GAATTTTTTTAAATTTTTTTAGTG TG 51.5 
CpG Island F2 F ATTTTTAGTAATTTAGGTTG 48.5  
CpG Island R1 R TCCAATAAATAAATTAAAAACC 48.5/51.5  
Region A (RICE ytre) F GGGGTTGGATGGGAATTGTGA 55  
Region A (RICE ytre) R CTCTACTACCTTTACCCAAAAACA 55  
Region A (RICE indre) F GTTTATAATTGTTGATAAGTATAAG 57  
Region A (RICE indre) R AAAACCCCACAACCTATCCC 57  
Region B (Fr. E) F TTGGGTGGTTAATTTAGAG  55 
Region B (Fr.E) R CTCAATACCCCCTTCCTAATCCTC  55 
Primers used for PCR screening and sequencing of TA cloned bacterial colonies 
M13 Forward F GTAAAACGACCCCCAG 50 
M13 Reverse R CAGGAAACACCTATGAC 50 
Primers used for PCR amplification of BRCA1 promoter from blood DNA for classical cloning into 
pGL4.10[luc2] 
BRCA1_KpnI F TGGCGGTACCGTACGTATCTTTTTAAG 56 
BRCA1_HindIII-R long R GGGCGCAAGCTTTTCTTTCTGTTCCAATG 56  
Primers used for sequencing of BRCA1 promoter cloned into pGL4.10[luc2] 
RV primer 3 F TAGCAAAATAGGCTGTCCC 50  
pGL4.10 MCS R R TGG CTTACCAACAGTACC 50  
BRCA1 F2 F GGCAAACTCAGGTAGAATTC 50  
BRCA1 promoter sekv S1 F CGTGAGCTCGCTGAGACTTCC 50  
BRCA1 lin.v.sekv S3 F GGGTTGGCAGCAATATGTGA 50 
Primers for site-directed mutagenesis  
SNP intro V1.1  F TATTCTTTGAGGGGGGGTAGG 60 
SNP intro V2.1 F TATTCTTTGACGGGGGGTAGGGG 60 
SNP intro common R CCCATCTGTCAGCTTCGG 60 
Primers used for introduction of site specific methylationª 
CpG 33 Met F 5’Phos CCTCCATTAGGGCmGGAAAGAGTGGGGG 53 
CpG 33 F 5’Phos CCTCCATTAGGGCGGAAAGAGTGGGGG 53 
CpG 33 R 5’Phos TCTCCAGTTTCGGTAAATATAAGTAATAAGG 53 
CpG 43-44 Met F 5’Phos CCAGAGCCCCmGAGAGACmGCTTGGCTC 63  
CpG 43-44 F 5’Phos CCAGAGCCCCGAGAGACGCTTGGCTC 63  
CpG 43-44 R 5’Phos ATTGGCCACCCAGTCTGCCCCCGG 63  
CpG 48-52 Met F 5’Phos TTCCmGTGGCAACmGGAAAAGCmGCmGGGAATTAC 60  
CpG 48-52 F 5’Phos TTCCGTGGCAACGGAAAAGCGCGGGAATTAC 60  
CpG 48-52 R 5’Phos ACCAAGGGGCTACCGCTAAGCAGCAGCC 60  
* Supplier: Sigma Aldrich 
ª A methylated cytosine is marked as Cm 
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Sequence (5’à3’) Annealing 
temp (°C) 
RPLP2 Primer F GACCGGCTCAACAAGGTTAT 55 
Primer R CCCCACCAGCAGGTACAC 55 
Probe Cy5-AGCTGAATGGAAAAAACATTGAAGACGTC-BBQ 55 
BRCA1  
WT total 
Primer F TGAAGCAGCATCTGGGTG 55 
Primer R GCTTCTAGTTCAGCCATTTCCTG 55 
Probe 6FAM-AGACTGCTCAGGGCTATCCTCTCAG-BBQ 55 
BRCA1  
WT a 
Primer F GCGTGAGCTCGCTGAGACTTC 61 
Primer R TGTGGAGACAGGTTCCTTGA 61 
Probe 6FAM-AGAGGGTGAAGGCCTCCTGAGCG--BBQ 61 
BRCA1  
WT b 
Primer F GACAGAGCGAGACTGTCTCAAAA 55 






Primer F ACGTGACTGCGCGTCGTG 61 
Primer R CGCAAACAGCAGATAAATCTATCTCTTTCTG 61 
Probe 6FAM-CCAGAACGTCTCAGCGAGCTCACGACG-BBQ 61 
BRCA1 
Pseudo b 
Primer F GACACTCCGTCTCAAAAAC 55 
Primer R GCAAACAGCAGATAAATCTATCTC 55 
Probe 6FAM-AGCCGGTGTTTATTTCTTTGTTTGTTT-BBQ 55 
*Supplier: TIB MOLBIOL 
 
3.8 Sequencing 
Table 3.8.1 Kit used in Sanger Sequencing 
Name Supplier (cat #) 
BigDye Terminator v1.1 cycle sequencing kit Thermo F. Scientific (4336774) 
 
3.9 Gel electrophoresis 
Table 3.9.1: Agarose gel electrophoresis reagents 
Name Supplier (cat #) 
Agarose Fisher Scientific (10366603) 
GelRed nucleic acid stain  Biotium (41003-1) 
GeneRuler DNA ladder  Fermentas (SM0331) 
jX174 Hae III digest TaKaRa (3405A) 
TAE-buffer  (see table 3.13.1) 
 
Table 3.9.2: (SDS)-Polyacrylamide gel electrophoresis (SDS-PAGE) reagents 
Name Supplier (cat #) 
10% Mini-PROTEAN TGX Precast Gel  Bio-Rad (4561036S) 
Trans-blot Turbo Mini Nitrocellulose transfer pack Bio-Rad (170-4158) 
Precision plus Protein WesternC Blotting Standard Bio-Rad (161-0376) 
PS11 protein marker GeneONe (310005) 
Mercaptoetanol Sigma Aldrich (M6250) 





3.10 Immunoblot and immunofluorescence 
Table 3.10.1: Antibodies  
Primary Antibody  Dilution* Host Supplier (cat #) Application 
Anti-BRCA1  1:1000 Rabbit Millipore (07-434) Western blot 
Anti-Actin  1:100 Rabbit Sigma Aldrich (A2066) Western blot 
Phospho-Histone H2a.X 
(Ser140)  
1:1500 Mouse Thermo Fisher 
Scientific (MA1-2022) 
Immunofluorescence  
Secondary Antibody Dilution Host Supplier (cat #) Application 




Alexa Fluor 488 goat 
anti-mouse IgG  




*Diluted in TBS-tween for western blotting and PBS for immunofluorescence (table 3.13.1) 
 
Table 3.10.2: Reagents and buffers used in immunoblot assay 
Name Supplier (cat #) 
Trans-Blot Turbo Midi Nitrocellulose Transfer Pack  Bio-Rad 
Tween20 Sigma Aldrich (P1379) 
BSA Sigma Aldrich (A2153) 
SuperSignal West Pico Chemilumeniscence Substrate Thermo Scientific (34080) 
SuperSignal West Femto Chemilumeniscence Substrate Thermo Scientific (34095) 
 
Table 3.10.3: Reagents used in immunofluorescence assay 
Name Supplier (cat #) 
Poly-L-Lycine Sigma Aldrich (P4832) 
37% Formaldehyde Sigma Aldrich (252549) 
Triton-X100 Sigma Aldrich (T8787) 
VectaShield HardSet Antifade Mounting medium with 
DAPI 
Vector Laboratories (H-1400) 
 
3.11 Site-specific methylation and Luciferase assay 
Table 3.11.1: Reagents used in site-specific methylation 
Name Supplier (cat #) 
Herculase II fusion polymerase Kit Agilent (600675) 
Taq DNA ligase  New England BioLabs (M0208S) 
Taq DNA ligase reaction buffer New England BioLabs (M0208S) 
NAD+  New England BioLabs (B90007S) 
dNTP  TaKaRa (4026, 4027, 4028, 4029) 
T4 DNA ligase TaKaRa (2011A) 
T4 Poly Nucleotid Kinase  New England Biolabs (M0201S) 
T4 polynucleotide buffer  New England Biolabs (B0201S) 
DpnI New England Biolabs (R0176S) 
10x NEB Buffer 2  New England Biolabs (B7002S) 
T7 exonuclease New England Biolabs (M0263S) 
10x NEB Buffer 4  New England Biolabs (B7004S) 
Dnmt1 New England Biolabs (M0230S) 
Shrimp Alkaline Phosphatase (rSAP) New England Biolabs (M0371S) 
 
Table 3.11.2: Kit used for luciferase assay 
Name Supplier (cat #) 
Dual-Glo® Luciferase Assay System Promega (E2920) 
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3.12 Long term cell culture experiment  
Table 3.12.1: Kits for cell proliferation assay, mycoplasma testing and STR profiling 
Name Supplier (cat #) 
GlobalFiler ID-X PCR Amplification Kit Applied Biosystems (4476137) 
GeneScan 600 LIZ Size Standard v2.0 Applied Biosystems (4408399) 
Venor GeM Mycoplasma Detection Kit  Sigma Aldrich (MP0025) 
WST-1 Cell proliferation Assay Kit  Roche Applied Science (05015944001) 
 
Table 3.12.2: Kits and reagents used in next generation sequencing 
Name Supplier (cat #) 
SeqCap EPI Accessory kit v.2 NimbleGen (07145519001) 
KAPA Library Preparation Kit KAPA Biosystems (07137974001) 
SeqCap Adapter Kit A NimbleGen (07141530001) 
EZ DNA Methylation Lightning Kit Zymo Research (D5030) 
SeqCap HE-Oligo Kit A NimbleGen (06777287001) 
SeqCap EZ Hybridization and Wash Kit NimbleGen (05634261001) 
SeqCap EZ Pure Capture Beads NimbleGen (06977952001) 
SeqCap Epi Choice Enrichment Kit  Nimblegen (07138989001) 
MiSeq Reagent kit v2, 300 cycles Illumina (MS-102-2002) 
Qubit dsDNA Broad Range Assay Kit Thermo Fisher Scientific (Q32850) 
Qubit dsDNA High Sensitivity Assay Kit Thermo Fisher Scientific (Q32854) 
Bioanalyazer DNA 1000 Kit (DNA Chip) Agilent Technologies (5067-1504) 
Bioanalyzer High Sensitivity Kit (+HS DNA Chip) Agilent Technologies (5067-4626) 
Phi X  Illumina (15017666) 
 
3.13 Buffers and Chemicals 
Table 3.13.1: General solutions and buffers 
Name Components Supplier  Application 
10x TAE Buffer  48.4 g Tris base, 20ml 0.5 M EDTA 
(pH 8.0), 11.44 ml Glacial acetic acid. 
ddH2O to 1L  
Sigma Aldrich 





5 mL ddH2O, 5 mL glycerol, Bromo 
phenol blue 




150g Tris, 710 g Glycine, 500 mL 10% 
SDS, ddH2O to 5 L 
Sigma Aldrich SDS-PAGE 
3x SDS – Gel 
Loading Dye  
7.5 mL 1M Tris-HCl (pH 6.8), 15 ml 
20% SDS, 317 mL 87% glycerol, 0.15 
g Bromo phenol blue, 5 mL MeOH, 
ddH2O to 50 mL 
 SDS-PAGE 
10x PBS 80 g NaCl, 2 g KCl, 14.4 g Na2HPO4, 
2.4 g KH2PO4, ddH2O to 1 L.  
Sigma Aldrich  
(KCl –VWR) 
Cell culturing  
10x TBS 24.2 g Tris base, 80 g NaCl, adjust pH 




10 g peptone, 5 g bacto yeast extract, 10 
g NaCl, 950 mL ddH2O 
Shake until solution is clear, adjust pH 
to 7.0 with NaOH. ddH2O to 1 L 
Sigma Aldrich 
(NaOH – VWR) 
E.coli culturing 
LB-Agar plates  
 
10 g Tryptone, 5 g yeast extract, 4 mL 
1N NaOH, 15 g Agar, 5 g NaCl. 
Autoclaved, add 100 µg/mL ampicillin. 
ddH2O to 1L.  




Low-TE Buffer Commercial Invitrogen STR-profiling, 
NGS libr. prep 
X-gal (20 
mg/mL) 
100 mg X-gal, 5 mL 
Dimethylformamide 
Sigma Aldrich Blue-white 
screening 
Rectified ethanol Antibac (600051) Multipurpose 
Absolutte ethanol Antibac (600068) Multipurpose 
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3.14 Instrument and Software 
Table 3.14.1: Instruments  
Name Supplier Application 
Microsentrifuge (16.000 g capability) Multiple Vendors Multipurpose 
NanoDrop ND-100 Spectrophotometer Qiagen Conc. measurements 
Qubit®3.0 Flurometer Thermo F. Scientific Conc. measurements 
Scepter™ 2.0 Handheld Automated Cell 
Counter 
Millipore  Cell culture work 
Mastercycler gradient (nexus) Eppendorf PCR 
Light Cycler® 480 II Roche qPCR 
FLUOstar Omega plate reader BMG LABTECH Bioluminescence 
Leica DM RTX microscope Leica Immunofluorescence 
Leica Fw4000 microscope Leica Immunofluorescence 
Molecular Imager Gel Doc EZ Imager Bio-Rad Agarose gel 
electrophoresis 
3500XL Genetic ANAlyser Thermo F. Scientific STR Profiling 
Trans-Blot® Turbo™ Transfer System Bio-Rad Western blot 
Applied Biosystems 3730 capillary sequencer Applied Biosystems Sanger sequencing 
Bioanalyzer 2100 Agilent 
Technologies 
NGS 
MiSeq deep sequencing system Illumina NGS 
DNA Vacuum Concentrator Multiple Vendors NGS 
Covaris Ultra Sonicator Covaris NGS 
Water Bath Multiple Vendors NGS 
 
Table 3.14.1: Software 
Name Supplier Application 
Light Cycler 480 software Roche RT-qPCR 
Sequence Scanner Applied Biosystems Sequence alignment 
4Peaks Nucleobytes Sequence alignment 
ClustalX v1.83 Conway Institute 
UCD Dublin 
Sequence alignment 
GneSnap SynGene Agarose gel 
electrophoresis 
Omega  BMG LABTECH Bioluminescence 













4.1 Cell culturing 
4.1.1 Propagation 
The breast cancer cell lines SKBR3, ZR-75-1, UACC-3199, BT549, T-47D, HCC38, 
MCF-7, MDA-MB 231, and MDA-MB 468 were cultured in recommended medium 
supplemented with 5-10 % FBS and 5% Pen/Strep, as listed in table 3.1.2. The cells 
were incubated in humidified air at 37˚C with 5% CO2 or without CO2. At 90% 
confluency, cells were split using trypsin-EDTA which causes the cells to detach from 
growth surface. Trypsin activity was neutralized by addition of fresh growth medium 
before re-seeding of cells. 
 
4.1.2 Harvesting of cells for DNA, RNA and protein analysis 
A homogenous cell suspension was transferred to 1.5 mL tubes and centrifuged (600 
G, at 4°C for 5 min) before medium was removed. All samples were immediately 
cooled on ice.  Cell pellets for DNA isolation were frozen at -20˚C. Cells collected for 
RNA analysis were lysed in 0.5 mL TRIzol and frozen at -80˚C. Samples for protein 
analysis (0.5 million cells) were dissolved in 0.2 mL protein lysis buffer (table 3.4.1) 
and frozen at -20˚C.  
 
4.1.3 Long term drug treatment of cell cultures  
SKBR3 cells were cultured (section 4.1.1) under the exposure of various doses of 
olaparib and doxorubicin for a period of 11-13 weeks (figure 4.1.). Each drug was 
dissolved in Dimethyl sulfoxide (DMSO), consequently a control sample treated with 
DMSO only was included in the long-term drug treatment. The final concentration of 
DMSO for all drug settings and DMSO treatment alone was 0.025%. Medium including 
drug was changed twice a week, and the cells were split when the confluence reached 
~90%. Medium and cells were harvested for subsequent analyses.  
 
When the long term experiment was initiated, concentrations much lower than half 
maximal inhibitory concentration (IC50) (described in section 4.2) were chosen due to 
the long time-period the cells would be exposed to the drugs (figure 1.4). Olaparib 
treatment was started at 1 µM and gradually increased to 8 µM, while doxorubicin 
treatment was started at 0.002 µM and increased to a maximum of 0.012 µM. The first 
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increase in drug concentration was done after four weeks, at which time a backup line 
was separated from the experiment line, in case the cells could not handle increase. The 
drug concentrations of doxorubicin and olaparib in the experiment lines were increased 
once a week until cell proliferation drastically decreased (max concentration the cells 
could handle), the drug concentrations were then decreased to allow more rapid 
proliferation again. Cells were harvested for DNA analysis for both drugs and both 
lines, as seen in figure 4.1 (filled squares). Olaparib treated cell were harvested at 11 
time points for the experiment line and 12 time points for the backup line. Cells were 
harvested at 7 time points for the experiment line and 12 time points for the backup line 
for the Doxorubicin treated cells. Time point zero was harvested before addition of 
drug, and is the same for all treatment settings.  
 
 
Figure 4.1:  Overview of long term treatment of SKBR3 cells. SKBR3 cells were treated over a time-
period of 11-13 weeks with the PARP-inhibitor olaparib (1-8 µM) and the chemotherapy doxorubicin 
(0.002-0.012 µM). The treated cells were split in two settings for each of the drugs; one experiment line 
and one backup line, indicated with dark and bright colors, respectively. Concentration (µM) was plotted 
against weeks of treatment. Time points of harvesting are marked with filled squares, and the samples 
analyzed by next-generation sequencing (explained in section 4.23) are marked with arrows. Harvesting 
at week zero was performed before addition of drugs.  
 
4.1.4 Mycoplasma test  
Mycoplasma test was performed on cell culture medium using the Venor GeM 
Mycoplasma Detection Kit by following the manufacturer’s instructions. The kit tests 
for all the known Mycoplasma, Acholeplasma and Ureaplasma species. Positive control 
DNA and Internal control DNA was included in all assays. The internal control 
containing a 191 bp DNA fragment, was co-amplified along with the samples.  
 
4.1.5 STR Profiling 
The GlobalFiler ID-X PCR Amplification Kit was used to confirm the identity and 
absence of cross contamination of cell lines of interest. The protocol was performed 




















































Low-TE buffer. In each run, negative control (Low-TE buffer), positive control (DNA 
control 007) and an allelic ladder were run in parallel. GeneScan 600 LIZ Size Standard 
v2.0 was added to all samples analyzed (internal size standard). The samples were run 
on a 3500 XL Genetic ANAlyser at Gade Laboratory for Pathology, Haukeland 
University Hospital, and analysed using the GeneMapper ID-X software.  
 
4.2 WST-1 assay 
The cell proliferation reagent WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolio]-1,3-benzene disulfonate) was used to evaluate the cytotoxic effect, measured 
as IC50, of the drugs doxorubicin and olaparib on the SKBR3 cell line. SKBR3 cells 
were seeded on a 96-well plate (6000 cells/well) and incubated with medium containing 
0.02 µM - 0.6 µM doxorubicin and 100 µM - 1000 µM olaparib for 96 h. DMSO treated 
cells were included in the assay to calculate background noise. Each treatment was 
performed with four parallels, and the assays were repeated three times for each drug. 
The cells were incubated at 37°C with WST-1 reagent (100 µL) for 1.5 h and the 
samples were measured by use of FLUOstar Omega plate reader (BIO LABTECH). 
DMSO treated cells were set as blank.  
 
4.3 Immunofluorescence assay 
SKBR3 cells (120 000) were seeded on poly-L-lysine pre-treated coverslips. SKBR3 
cells were treated with the drugs olaparib (1-2 µM), doxorubicin (0.002-0.004 µM) or 
DMSO (control) for 48 h. Additional controls to check the specificity of the antibody 
were included in the assay; cells treated with the highest dose (2 µM for olaparib and 
0.004 µM for doxorubicin) were incubated with primary antibody only and secondary 
antibody only to look for any detectable signal. The cells were washed with 1x PBS 
(500 µL) twice, before fixation with 4% formaldehyde in 1% PBS (1mL) for 15 min at 
RT. The cells were again washed 3x 5 min with PBS (500 µL) at RT, followed by 
permeabilisation using 0.1% Triton-X-100 in ddH2O (1 mL) for 10 min at RT. After 
washing with 1x PBS (500µL), blocking was performed by incubating the cells with 
1% BSA in 1x PBS (30 µL) for 30 min. The cells were then incubated with the primary 
antibody Phospho-Histone H2A.X (Ser140) anti-mouse, 1:1500 dilution in 1% BSA in 
1x PBS for 1 hour at RT. The cells were washed 3x 10 min in 1x PBS (30µL) at RT 
before incubation with 1:200 diluted secondary antibody Alexa Fluor 488 goat anti-
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mouse IgG (2 mg/mL), tagged with fluorescein isothiocyanate (FITC) in 1% BSA in 
1x PBS for 1 hour in the dark at RT. Cells were washed in same manner as after primary 
antibody incubation before mounting using Vectashield HardSet antifade mounting 
medium with DAPI on a microscope slide. Samples were stored in the dark at 4°C 
overnight before pictures were taken using a Leica DM RTX microscope and the Leica 
Fw4000 software. To count the total number of cells DAPI stain was used, the positive 
cells were characterized by green fluorescent signal (FITC) and granulation. A 
minimum of 100 cells were counted for each sample and the experiment was repeated 
three times. Average and standard deviation of three parallel experiments were 
estimated (statistical analyses are described in section 4.22).  
 
4.4 Transfection 
Lipofectamine LTX Reagent with PLUS reagent was used for transfection of cultured 
cells. For each sample, two tubes containing optimum medium (400 µL, room 
temperature) were prepared. To one of the tubes, Plus reagent (5 µL) and a total of 1000 
ng plasmid DNA (700 ng BRCA1 promoter-pGL4.10[luc2] + 300 ng pCMV-
cytoEGFP) was added. In the second tube, Lipofectamine LTX (10 µL) was added. 
After 10 min incubation, the contents of the two tubes were mixed followed by 
incubation for 20 minutes. The transfection mixture (100 µL) was added to the cells 
(10 000 cells in 100 µL medium mix) in 96-well plate (Greiner BioOne, 96-wells, white 
(transparent bottom)). Transfection reagents were removed and replaced with fresh 
medium after 24 h. As positive and negative controls for luciferase expression, the 
vector pGL4.13[luc2/SV40] containing the strong SV40 promoter and reporter gene 
luciferase and the empty vector pGL4.10 were used, respectively. Each sample was co 
transfected with the eGFP expressing pCMV-cytoEGFP vector in order to enable 
correction for transfection efficacy. The experiment was repeated seven times.  
 
4.5 DNA extraction from cell pellets 
DNA was extracted from harvested cell pellets by using the QIAGEN QIAamp DNA 
Mini Kit for DNA purification according to the manufacturer’s instructions, samples 
were eluted in elution buffer. 
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4.6 Determination of RNA and DNA concentration 
Determination of both DNA and RNA concentrations were performed for the samples 
of interest by use of NanoDrop spectrophotometer. Average of three measurements was 
used for concentration determination for each sample.  
 
Qubit dsDNA BR Assay Kit were used to determine concentration of samples for 
Methylation specific massive parallel sequencing (section 4.23). Measurements were 
performed according to manufacturer’s protocol.  
 
4.7 Bisulfite conversion of DNA  
Bisulfite conversion of purified DNA for investigation of methylation was performed 
by EZ DNA Methylation-Gold Kit using 200 - 500 ng input DNA. Cp Genome 
Universal Methylated DNA (methylated positive control), CRL-5803 lung carcinoma 
cell line DNA (negative control) and ddH2O (negative control) were included in each 
set up.  
 
4.8 PCR amplification 
AmpliTaq Gold polymerase (Table 3.6.1) was used for PCR amplification of the 
BRCA1 promoter region from bisulfite converted DNA obtained from breast cancer cell 
lines (subsequent to TA cloning) for determination of the methylation pattern. As the 
bisulfite treatment causes DNA to fragment, the region of interest was amplified as 
three shorter fragments in separate PCR reactions, termed CpG Island, Region A and 
Region B. The fragments were PCR amplified using 200-500 ng (2-3 µL) bisulfite 
converted DNA (section 4.7) as template in 1st round of PCR. Fragment CpG Island 
and Promoter A were amplified by nested PCR, while only one round of amplification 
was performed for Region B. Primers are described in table 3.7.1 and an overview of 








Table 4.8.1 Reagents used for PCR amplification with AmpliTaq Gold polymerase 
Reagents  Final conc.  
AmpliTaq Gold polymerase (5 U/µL) 0.5 µL 
10x Gold PCR Buffer u/MgCl2 5.0 µL 
MgCl2 (25) mM 3.0 µL 
dNTP (2 mM) 2.5 µL 
Forward primer 10 mM 1.0 µL 
Reverse primer 10 mM 1.0 µL 
Bisulfite converted DNA template or 1. Round PCR product 1-3 µL 
ddH2O total volume of 50 µL 
 
Table 4.8.2: PCR programs used for amplification of fragment CpG Island   
PCR program: CpG Island 1.r   PCR program: CpG Island 2.r  
94 °C 5 min    94 °C 5 min   
94 °C 30 sec 
35 cycles 
 94 °C 30 sec 
40 cycles 51 °C 30 sec  48.5 °C 30 sec 
72 °C 50 sec  72 °C 50 sec 
72 °C 5 min     72 °C 5 min    
10 °C Hold   10 °C Hold  
 
Table 4.8.3: PCR programs used for amplification of fragment Region A   
PCR program: Region A 1.r   PCR program: Region A 2.r  
95 °C 5 min    95 °C 5 min   
95 °C 1 min 
35 cycles 
 95 °C 1 min 
35 cycles 55 °C 3 min  57 °C 3 min 
72 °C 1 min   72 °C 1 min  
72 °C 5 min     72 °C 5 min    
10 °C Hold   10 °C Hold  
 
Table 4.8.4: PCR programs used for amplification of fragment Region B   
PCR program: Region B  
95 °C 5 min    
95 °C 1 min  
40 cycles 
 
55 °C 3 min  
72 °C 1 min   
72 °C 5 min     
10 °C Hold   
 
The VWR Taq DNA polymerase (table 3.6.1) was used for PCR amplification in two 
settings; 1) For screening of bacteria colonies resulting from TA cloning of bisulfite 
convert DNA corresponding to BRCA1 promoter in breast cancer cell lines, and 2) PCR 
amplification of the BRCA1 promoter from non-converted DNA purified from blood 
for subsequent cloning into the vector pGL4.10[luc2] (table 3.2.1) using restriction 
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enzymes (RE). Primers are listed in table 3.7.1 and reaction components and PCR 
programs are described in table 4.8.5 and 4.8.6-4.8.7.  
 
Table 4.8.5 Reagents used for PCR amplification with VWR Taq DNA polymerase  
Reagent  Volume 
VWR Taq DNA polymerase (5U/µL) 0.25 µL 
10 x Key Buffer 2.5 µL 
dNTP (0.8 µM) 0.5 µL 
M13 F (10 µM) 0.5 µL 
M13 R (10 µM) 0.5 µL 
DNA template  X µL 
ddH2O  to a total of 25 µL 
 
Table 4.8.6: PCR programs for screening of bacteria colonies following TA cloning of 
bisulfite converted DNA  
PCR program: Screening PCR for bacterial colonies  
95 °C 10 min    
95 °C 30 sec  
35 cycles 
 
52 °C 30 sec  
72 °C 1 min   
72 °C 5 min     
10 °C Hold   
 
Table 4.8.7: PCR program for amplification of BRCA1 promoter from blood DNA for 
subsequent cloning into pGL4.10[luc2] using restriction enzymes 
PCR program: RE Cloning  
95 °C 10 min    
95 °C 30 sec  
40 cycles 
 
56 °C 30 sec  
72 °C 2 min   
72 °C 5 min     
10 °C Hold   
 
4.9 Agarose gel electrophoresis  
Agarose gel electrophoresis was performed for analysis of DNA products. GelRed 
(0.01%) was added to 1-2% agarose dissolved in 1x TAE-buffer. The polymerized gel 
was transferred to a running chamber with TAE-buffer. Samples were loaded with 6x 
DNA loading buffer (final concentration 1x) and the gels were run at 100 V for 
approximately 1 h. The Molecular markers HaeIII digest and Generuler DNA ladder 
mix with pre-determined fragment sizes were run in parallel and used to estimate the 
size of the DNA in the samples. Molecular Imager Gel Doc EZ Imager from Bio-Rad 
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was used along with the software GeneSnap from SynGene to visualize and document 
the DNA fragments by UV light.  
 
4.10 Gel purification 
Samples were loaded and run on an 1% agarose gel (section 4.9). Bands of interest were 
cut from the gel using a scalpel and purified using Illustra GFX PCR DNA and Gel 
Band purification kit.   
 
4.11 TOPO TA Cloning  
PCR products (1-5 µL; 100-500 ng) were TOPO TA cloned into pCR2.1-TOPO vector 
followed by transformation into One Shot TOP 10 E. Coli chemically component cells 
according to instruction from the manufacturer (TOPO TA cloning kit). Samples older 
than one week were re-adenylated before cloning by addition of dNTP (10mM) and 
Dynazyme Ext (1 U/µL) to the PCR product and incubated at 72°C for 30 min. E. Coli 
cells were plated on LB-plates containing X-gal (for blue/white screening) and 
ampicillin. Screening PCR followed by agarose gel analysis (1%) was used for 
selection of colonies that contained insert of correct size as described in in section 4.8 
and 4.9. 
 
4.12 Restriction Enzyme cloning  
The vector pGL4.10[luc2] and PCR product containing BRCA1 promoter amplified 
from non-converted blood DNA were cut with the restriction enzymes KpnI-HF and 
HindIII for 1 h at 37°C. Reaction components are listed in table 4.12.1-4.12.2.   
 
Table 4.12.1: Reagents used for RE cutting of vector pGL4.10[luc2] 
Reagent Volume 
10x CutSmart NEB Buffer  2 µL 
KpnI-HF 20 U/µL 1 µL 
HindIII-HF 20 U/µL 1 µL 
Vector pGL4.10[Luc2] (1µg/µL) 1.3 µL 
ddH2O  To a total of 20 µL 
 
Table 4.12.2: Reagents used for RE cutting of PCR amplified BRCA1 promoter  
Reagent Volume 
10x Cutsmart NEB Buffer 5 µL 
KpnI-HF 20 U/µL 1 µL 
HindIII-HF 20 U/µL 1 µL 
PCR product  12.5 µL 
ddH2O To a total of 50 µL 
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To prevent re-ligation of the vector pGL4.10[luc2] after restriction enzyme cutting, the 
vector was dephosphorylated by rSAP (1.0 µL, 1.0 U) at 37°C for 45 min, followed by 
heat inactivation at 80°C for 20 min. The cut and dephosphorylated vector, as well as 
the BRCA1 promoter PCR product was purified by agarose gel purification (section 
4.10). The BRCA1 promoter PCR product was ligated into the vector pGL4.10 by T4 
DNA ligase at 16°C overnight using a vector:insert molar ratio of ~1:10. Reaction 
components are listed in table 4.12.3.  
 
Table 4.12.3 Reagents used for ligation of BRCA1 promoter PCR product into 
pGL4.10[luc2] 
Reagent Volume 
T4 DNA Ligase (350 U/µL) 1 µL 
10x T4 DNA ligase buffer  2 µL 
pGL4.10[luc2] cut with KpnI-HF/HindIII-HF (60.2 ng/µL) 0.9 µL 
BRCA1 promoter PCR cut with KpnI-HF/HindIII-HF (23.7 ng/µL) 9.7 µL  
ddH2O to a total of 20 µL 
 
The ligation mixture (0.5 µL) was transformed into competent TOP 10 E. coli cells as 
described in section 4.11. 
 
4.13 Bacteria culturing 
Bacteria colonies harboring plasmid containing insert of correct size were selected and 
cultured in LB-medium with ampicillin (0.05%) at 37°C and 250 RPM overnight. 
Cultures of 1 mL and 150 ml LB-medium were prepared for miniprep and maxiprep, 
respectively.   
 
4.14 Plasmid purification  
Plasmids were purified from bacteria cultures using QIAprep Spin, miniprep kit or 
HiSpeed Plasmid purification, Maxi Prep kit. Both protocols were performed according 




4.15 Sanger Sequencing 
Sanger sequencing was performed using the BigDye Terminator v1.1 cycle sequencing 
kit and the relevant primers (table 3.7.1). Capillary electrophoresis and data collection 
were performed on an Applied Biosystems 3730 capillary sequencer at the Center of 
Medical Genetics and Molecular Medicine at Haukeland University Hospital. All 
sequences were analyzed in 4Peaks/Sequence Scanner and compared to reference 
sequence GenBank U37574.1 using Clustal X (v2.1). Reaction components and PCR 
program are listed in table 4.14.1-4.14.2.  
 
Table 4.14.1 Reagents used for Sanger Sequencing 
Reagents Volume 
5x BigDye Terminator v1.1 Sequencing Buffer 5 µL 
BigDye Terminator v1.1 Ready reaction Mix 0.5 µL 
Primer (10 µM) 1 µL 
DNA template  X µL 
ddH2O To a total of 10 µL 
 
Table 4.14.2 PCR program used for Sanger Sequencing 
PCR program: Sanger sequencing 
94 °C 5 min   
94 °C 15 sec 
30 cycles 50 °C 5 sec 
60 °C 4 min  
10 °C Hold  
 
4.16 RNA purification 
RNA was purified from cell pellets using the TRIzol Reagent according to the 
manufacturer’s instructions. Chloroform (CHCl3) was added to the TRIzol lysate, 
resulting in a separation of the fluid into three distinct layers; an upper aqueous layer 
containing RNA, an intermediate layer, and a lower organic layer containing DNA. 
Isopropanol was used to precipitate the RNA from the aqueous layer. The only 
exception from the recommended protocol was that samples were incubated in 
isopropanol for 40 min at -20°C, instead of 10 min at RT. The RNA concentration was 
determined by Nanodrop and the samples were stored at -80˚C.  
 
4.17 cDNA synthesis 
Purified RNA (500 ng) was converted to complementary DNA (cDNA) by using the 
Quanta Biosciences qScript dDNA Supermix Kit. Protocol was performed according 
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to the instructions of the manufacture. Samples were diluted 1:10 in nuclease free 
ddH20 and stored at -20°C. 
 
4.18 qPCR 
Quantitative PCR (qPCR) was performed to determine the expression levels of 
transcripts of interest by use of LightCycler 480 Probes Master and a hydrolysis probe 
assay containing a fluorescence reporter dye and quencher. Position of primers and 
probes, as well as the specific nucleotide sequence can be found in appendix 1 (figure 
A.1) Relative mRNA levels of the samples were calculated by using in-run standard 
curves (kindly provided by Elisabet Ognedal Berge) to convert crossing point (CP) 
values for the gene of interest to concentrations. All CP values above 40 were 
considered below the sensitivity limit for mRNA detection, and concentrations for such 
samples were set to zero. A minimum of five runs were performed for each assay and 
the extreme upper and lower values were excluded when calculating average relative 
mRNA levels. For each assay, an internal calibrator (pooled cDNA from five heathy 
donors, kindly provided by Elisabet Ognedal Berge) was included in every parallel run 
to correct for potential run-to-run variations. The housekeeping gene RPLP2 (encoding 
ribosomal protein P2) was used as a reference gene to correct for any differences 
between the samples in each assay caused by variation in amount of input cDNA 
(loading control). The samples were run on a LightCycler 480 machine and analyzed 
in the corresponding Light Cycler 480 software (version 1.5.1).  
 
Exact comparisons of data across assays (e.g. concentrations of BRCA1 WT a versus 
BRCA1 b or versus BRCA1 WT total) were not possible due to different reaction 
efficacies between the different assays. Thus, for this purpose, a ΔΔCP-approach was 
applied, assuming a perfect (2-fold per cycle) efficacy of all assays. In this method, the 
difference in CP-values between the respective target genes (BRCA1 WT a or WT b) 
and the reference gene (BRCA1 WT) total were first calculated (equation 4.1). Then, 
these ΔCT-values were converted to relative concentrations by applying 2 as the 
efficiency number, instead of using standard curves (Δ concentration between two 
transcripts = 2ΔCP). Primers and probes are listed in table 3.7.2, reaction components 
are described in tables 4.18.1 and 4.18.2, and the thermocycler program are described 





∆𝐶𝑇 = 𝐶𝑇	 𝑡𝑎𝑟𝑔𝑒𝑡	𝑔𝑒𝑛𝑒 − 𝐶𝑇	(𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒	𝑔𝑒𝑛𝑒) 
 
Table 4.18.1: Reagents used for preparations of primer/probe mix 
Reagent Volume 
Forward Primer (50 µM) 10 µL 
Reverse primer (50 µM) 10 µL 
Probe (50 µM) 2.5 µL 
ddH2O to a total of 100 µL 
 
Table 4.18.2: Reagents used for preparations of reaction master mix 
Reagent Volume 
2x LightCycler 480 probes master 10 µL 
Primer/probe mix (specific for each assay, table 3.7.2) 2 µL 
Template 5 µL 
ddH2O to a total of 20 µL 
 
Table 4.18.3: qPCR program  
qPCR program: BRCA1 mRNA levels 
95 °C 5 min    
95 °C 10 sec 50 cycles 
 
X °C 25 sec  
40 °C 10 sec    
*Annealing temperature (X) for each specific reaction is listed in table 3.7.2  
 
4.19 Western blot analysis 
The relative protein levels were analyzed by Western blot (WB) analysis. Cell pellets 
lysed in protein lysis buffer (20 µL) was boiled with sample loading buffer (10µL, see 
table 3.13.1) at 95°C for 10 min. Protein samples were loaded on a 10% polyacrylamide 
gel along with BioRad Precision plus standard or molecular size ladder PS11. Samples 
were run at 100 V for 10 min followed by 150 V for 45 min. Commercial blot 
membrane was prepared, and the proteins were transferred from the gel to the 
nitrocellulose membrane by use of the Trans-Blot Turbo Transfer System. The 
membrane was blocked in 5% BSA diluted in 0.05% TBST for 1h at RT. Excess BSA 
was removed by a quick wash in 0.05% TBST before the membrane was incubated 
with primary antibody.  
 
For BRCA1 protein analysis, a 1:1000 dilution (in 0.05% TBST) of the primary 
antibody Anti-BRCA1 (Millipore, Rabbit antiserum) was incubated overnight at 4°C 
on shaker. The membrane was washed in 0.05% TBST (3x10 min on shaker at RT) 
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before incubation with 1:1000 dilution (in 0.05% TBST) of the secondary antibody 
Anti-Rabbit ECC HRP (GE Health Care) 1h at RT. The membrane was again washed 
with 0.05% TBST (3x 10 min on shaker at RT) and 1x TBS (1x 5 min on shaker at RT) 
before development using chemiluminescent substrate horseradish peroxidase 
(SuperSignal West Pico (200 µL) and Femto (600 µL)) on FUJIFILM-LAS 4000 (~60 
s exposure).  
 
To ensure equal loading of the samples, the membrane was again washed before 
incubation (1h, on shaker at RT) with 1:100 (in 0.05% TBST) of the primary antibody 
anti-actin (Sigma A2060 Rabbit). The membrane was washed with 0.05% TBST (3x 
10 min on shaker at RT) before incubation (1h on shaker at RT) with 1:1000 dilution 
(in 0.05% TBST) of secondary anti-body Anti-Rabbit ECC HRP (GE Health Care). The 
membrane was then washed in 0.05% TBST (3x 10 min on shaker at RT) as well as 
with 1x TBS (1x 5 min on shaker at RT) before developed as described above with 
exposure time ~2 sec.  
 
4.20 Site specific methylation 
Introduction of DNA methylation at specific sites of interest in the BRCA1 promoter- 
pGL4.10[luc2] construct was performed as described by Han et. al (Han et al., 2013). 
The protocol consists of four main steps: 1) combined PCR and ligation reaction, 2) 
digestion by DpnI and T7 exonuclease treatment, 3) methylation by Dnmt1, and 4) 
verification by bisulfite sequencing (figure 4.2).  
 
Figure 4.2 Overview of site-specific methylation protocol as described by Han et. al. The protocol 
consists of four main steps. Step 1: In the combined PCR and ligation reaction, primers designed to 
harbor methylation in positions of interest are used to amplify vector construct by PCR. The DNA 
polymerase creates a nicked template which is ligated directly by Taq DNA ligase. Step 2: Digestion of 
parental DNA and un-ligated DNA by DpnI and T7 exonuclease, respectively. Step 3: Methylation of 
hemi-methylated template by Dnmt1. Step 4: Verification of methylation pattern by bisulfite sequencing. 
Methylated CpG’s are marked with a red cross in the figure. Reproduced with permission from (Han et 
al., 2013), copyright Taylor & Francis group.  
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In the first step, primers with 5’-end phosphorylation, designed to harbor methylation 
at CpG site of interest (see table 3.7.1) were used in combination with a DNA 
polymerase without stand displacement activity, to generate a complementary DNA 
strand with a nick which could subsequently be ligated by Taq DNA ligase. Gradient 
PCR was performed prior to experiment start to determine best annealing temperatures 
for each primer set. For each PCR using methylated primers, an additional PCR reaction 
with corresponding unmethylated primers was performed as a negative control 
Reaction components are described in table 4.20.1 and PCR program in table 4.20.2.  
 
Table 4.20.1: Reagents used for combined PCR and ligation 
Reagent Volume 
Herculase II fusion polymerase  0.5 µL  
5x Herculase II reaction buffer 10 µL 
Taq DNA ligase (40 U/µL) 4 µL 
NAD+ (50mM) 1 µL 
dNTP (0.8 M) 5 µL 
Forward primer, with/without methylation (10 µM) 1.25 µL 
Reverse primer, without modification (10 µM) 1.25 µL 
BRCA1 promoter -pGL4.10[luc2] (10 ng/µL) 1 µL 
ddH20  Total volume of 50 µL 
 
Table 4.20.2: PCR program for combined PCR and ligation  
PCR program: Combined PCR and ligation    
98°C 2 min    
98 °C 20 sec  
35-40 cycles 
 
* 30 sec  
72°C 3.5 min   
65 °C 5 min     
4 °C Hold   
*Annealing temperatures according to primer are listed in table 4.7.1 
 
The sample was purified using GFX PCR DNA and Gel Band Purification Kit (GE 
Healthcare) by following the manufacturer’s instructions (section 4.10). Samples were 
eluted with 2x 25µL sterile nuclease-free water and treated with DpnI at 37°C for 1 
hour to digest the parental plasmid. Reaction components are listed in table 4.20.3.  
 
Table 4.20.3: Reagents used for DpnI treatment of PCR-ligation product 
Reagent Volume 
DpnI (20 µL) 1 µL  
10x NEB Buffer 2 5 µL  
PCR-ligation product 45 µL (50 µL total reaction volume) 
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The DpnI treatment was followed by a second round of clean up in the same manner as 
previously described (section 4.9). In order to remove un-ligated linear PCR product, 
T7 exonuclease was added, and the reaction mixture was incubated at 25°C overnight. 
Reaction components are listed in table 4.20.4. 
 
Table 4.20.4: Reagents used for T7-exonuclease treatment of DpnI-treated PCR-
ligation product 
Reagent Volume 
T7 exonuclease (10 U/µL) 2 µL 
10x NEB Buffer 4  5 µL  
DpnI treated PCR-ligation product 43 µL(50 µL total reaction volume) 
 
Samples were purified by GFX PCR DNA and Gel Band purification kit (GE 
Healthcare) and run on agarose gel (1%) with DNA ladder GeneRuler (Fermentas) for 
visual inspection. 
 
Finally, Dnmt1, which is specific for hemi-methylated DNA, was added to methylate 
the complementary strand at the positions corresponding to the methylated sites in the 
primers. The reaction was performed at 37°C for 4 hours. After two hours, additional 
S-Adenosyl methionine (SAM) was added. Reaction components are listed in table 
4.20.5. 
 
Table 4.20.5: Reagents used for Dnmt1 treatment of T7 and DpnI treated PCR –ligation 
product 
Reagent Volume/amount 
10x Dnmt1 reaction buffer 5 µL 
BSA (5mg/mL) 1 µL 
SAM (8 mM 1 µL x2 (added at two time points) 
Dnmt1 (2 U/µL) 2 µL 
T7 and -DpnI treated PCR-ligated product 2 µg 
ddH2O Total volume of 50 µL 
 




4.21 Site-directed mutagenesis 
Site-specific methylation was performed using Q5 Site-Directed Mutagenesis Kit 
Protocol and relevant primers (table 3.7.1). Reaction components are listed in table 
4.21.1 and the PCR program is listed in table 4.21.2. 
Table 4.21.1 Reagents for site-directed mutagenesis 
Reagent Volume 
Q5 Hot Start High-fidelity 2x Master Mix 12.5 µL 
Forward primer (10 µM) 1.25 µL 
Reverse primer (10 µM) 1.25 µL 
Template DNA (1-25 ng) 1 µL 
Nuclease-free water Total volume of 50 µL 
 
Table 4.21.2 PCR program for site-directed mutagenesis 
PCR program: site-directed mutagenesis 
98 °C 30 s    
98 °C 10 s 25 cycles 
 
X °C 30 s  
72 °C 3.5 min   
72 °C 2 min    
X: annealing temperature for each specific primer used is listed in table 3.7.1. 
 
4.22 Luciferase assay 
The Dual-Glo Luciferase assay system was performed to assess variations in firefly 
luciferase expression levels due to variation within the BRCA1 promoter. The vector 
pCMV-cytoEGFP was included for normalization of transfection efficiency, cell count 
differences and pipetting variations. Approximately 48 h after transfection, GFP was 
measured before addition of luciferase reagents. Each sample was analyzed in six 
parallels in each of the seven assays on a FLUORstar Omega plate reader.  
 
4.23 Methylation specific massive parallel sequencing 
4.23.1 Library preparations 
Library preparations were performed using the Roche NimbleGen SecCap Epi 
Enrichment System, following the protocol recommended by Roche (Version 1.2, 
appendix 2) in combination with custom made probe design (SeqCap Epi Choice). 
Reagents and instruments are listed in table 3.12.2 and 3.14.1, respectively. In short, 
purified sample DNA (1 µg), concentration determined by use of Qubit dsDNA BR 
Assay kit (section 4.6), were mixed with bisulfite conversion control (Lambda DNA) 
and fragmented followed by end repair and A-tailing to permit subsequent adapter 
ligation (universal and index adapters). The DNA was then bisulfite converted followed 
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by pre-hybridization PCR. During hybridization, the samples were mixed with a 
custom-made probes design, allowing analysis only of regions of interest. The probes, 
designed by Elisabet Ognedal Berge in collaboration with Roche, are intended to target 
358 regions from the promoter region of 283 tumor suppressor genes. The selection of 
genes was based on cancer gene lists from the Welcome Trust Sanger Institute and 
Roche (Comprehensive Cancer Design), as well as manual literature search to cover as 
many tumor suppressor genes as possible, independent of cancer type (PanCan). For 
each gene, a region spanning from approximately 1500 bp upstream to 500 bp 
downstream from the transcription start site (TSS) was covered. The probes were 
designed to bind target DNA in all possible methylation configurations (fully 
methylated, partially methylated and completely unmethylated) on both DNA strands, 
enabling correction for potential overlap between CpGs and SNPs. The probes, bound 
to the target region, were marked with biotin and captured using streptavidin coated 
beads. After post-hybridization PCR, samples were pooled and mixed with PhiX library 
(10% spike-in). The multiplex DNA library samples were run on the Illumina MiSeq 
instrument (Figure 4.3).  
 
4.23.2 Clustering and sequencing 
Cluster generation and sequencing were performed in fully automated processes on a 
MiSeq massive parallel sequencer (Illumina). Sequencing was set to generate paired 
end reads, with a 100 bp length per read. 
 
4.23.3 Bioinformatic data analysis 
Analysis of data generated by the NimbleGen SeqCap Epi Enrichment System was 
performed by Zuzana Sichmanova, using publically available open source analysis 
tools as described in (appendix 3) and figure 4.3.  
 
In short, the output from the Illumina MiSeq runs are provided as FASTQ files, a text-
based format for storing both a biological sequence and its corresponding quality scores 
(Phred quality score). Before mapping, reads were trimmed for adapters and sequences 
of poor quality (QC< 20) as well as reads shorter than 75 bp by Trimmomatic. The 
reads were then aligned using the bisulfite mapping software BSMAP. After sorting the 
reads into top and bottom strands, the program Piccard was used to remove duplicates 
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based on identical 5’ starting point, before top and bottom strands again were merged. 
Bamtools was used to filter for properly paired reads, restricting the analysis only to 
reads pairs where the two mates are mapped at a correct orientation and at a distance 
corresponding to the insert size of the library. To avoid bias, overlap between read 1 
and read 2 in a pair caused by difference in library insert size, was clipped using 
BamUtil. Various metrics were calculated including count on target reads and depth of 
coverage by the program Picard. The methylation percentage of each individual CpG 
was determined by use of BSMAP, which also determines the bisulfite conversion 




Figure 4.3: Overview of wet-lab and dry-lab workflow for Roche NimbleGen SecCap Epi 
Enrichment Systems. A) Library preparations was performed on methylated DNA to enable adaper 
ligation. Bisulfite conversion was performed on the DNA sample before hybridization with custom made 
probes, designed to bind all possible methylation configurations. Probes bound to target DNA was 
captured using streptavidin coated beads before amplification by PCR and subsequent sequencing on 
Illumina MiSeq. B) After sequencing, the resulting FastQ files were extracted and run through a 
bioinformatic pipeline to extract information about the methylation pattern of the promoter in the samples 
of interest. All tools used are publically available open source tools. The pipeline was designed in 




4.24 Statistical analyses 
Categorical variables were compared between groups using Pearson’s Chi-squared test. 
Continuous variables were compared between groups using unpaired student’s t-test. 
Correlation between two continuous variables was estimated by Spearman test 
(Spearman’s Rho). All p-values were reported as two-sided and p-values <0.05 were 






























Experiments were performed to increase the understanding of the biological roles of 
BRCA1 promoter methylation, both in terms of global methylation of the promoter 
region and in terms of methylation of individual CpGs. With this overall aim in mind, 
three sub aims for the present project were outlined; 1) Assessment of BRCA1 
methylation patterns in a panel of breast cancer cell lines and analysis of correlation 
between methylation in BRCA1 promoter region and mRNA and protein expression. 2) 
Investigate how the ratio between the a and b transcripts is affected by alterations in 
the a and b promoter region of BRCA1, including methylation of specific CpGs as well 
as polymorphic variants existing in the general population. 3) Analyze the effect of long 
term drug treatment on methylation levels in the BRCA1 promoter.  
 
 
Figure 5.1: CpGs and potential transcription binding sites in BRCA1 promoter region. CpGs 
assessed in this study are marked in read and number from 1-66, with one CpG not included in the 
numeration due to a SNP (marked in turquoise, position 1802) where the C nucleotide can be substituted 
with G. Potential transcription factor binding sites, found described in the literature, are marked with 
boxes and corresponding name inside the box, exon 1a is marked with grey color and exon 1b is marked 
with blue color, transcription start site is marked with a green arrow. If present, polymorphism AAC is 


















































5.1 Assessment of BRCA1 methylation patterns in a panel of breast cancer 
cell lines and analysis of correlation between methylation in BRCA1 
promoter region and mRNA and protein expression  
In this section, experiments for analysis of the methylation pattern in the BRCA1 
promoter region as well as mRNA and protein levels for a panel of nine breast cancer 
cell lines are described. All cell lines were choses on the basis that they were breast 
cancer cell lines and had wild type (WT) BRCA1 (Hollestelle et al., 2010, Elstrodt et 
al., 2006), further characteristics of each cell line is given in table 3.1.1. These cell lines 
were cultured by Elisabet Ognedal Berge and Reham Helwa in the period from 
December 2015 to April 2016. 
 
5.1.1 Methylation in BRCA1 promoter in a panel of breast cancer cell lines 
For assessment of BRCA1 promoter methylation at the individual CpG-level, three 
fragments were amplified from bisulfite converted DNA from a panel of nine breast 
cancer cell lines. These fragments, covering different but overlapping regions of the 
BRCA1 promoter, were termed CpG Island, Region A and Region B. The amplification 
of all three regions yielded products of the expected molecular sizes: 552, 660, and 490 
bp, respectively (figure 5.2).  
 
 
Figure 5.2: BRCA1 promoter region amplified from bisulfite converted DNA for nine breast cancer 
cell lines. The region was amplified in three separate PCR reactions named Island, Region A and Region 
B. CpG Island and Region A were amplified by nested PCR and the PCR product from the second round 
is shown in the figure. The positive controls CpG Genome Universal methylated DNA (K+) and negative 
controls (U+ (cell line CRL-5803)), ddH2O and master mix (MM) were included. All nine cell lines were 
amplified in one set up for fragment CpG Island and Region A, while PCR products were retrieved from 
three sett ups for fragment Region B. Samples that were not used or well that are empty are marked with 
and red x. Samples were run in a 1% agarose gel with DNA marker jX174-Hae III.  
 
Each PCR product was subsequently inserted into the pCR2.1-TOPO vector by TA-





























were analyzed by PCR screening (section 4.8). Colonies harboring plasmid with insert 
of correct size for each of the fragments were selected and cultured before purification 
(mini-prep, section 4.14) and Sanger sequencing (section 4.15). A minimum of 20 
colonies revealing sequences of high quality for each fragment and cell line were 
obtained and aligned with reference sequence U37574.1 (GeneBank), all together 
covering a region spanning from -1089 to +330 relative to transcription start site, 
including a total of 66 CpG dinucleotides (figure 5.3). The CpGs are located in positions 
between -1052 to +302, relative to transcription start site of BRCA1 in GeneBank 
sequence U37574.1. For further assessment the CpGs were numbered 1-66 with CpG 
1 being in position -1052 and CpG 66 being in position +302. Nucleotide sequence and 
position of all 66 CpGs can be found in figure 5.1.  
 
The bisulfite conversion rate was calculated to be 99.63%, found by counting the 
number of Cs and Ts in the cloned regions (in the 20 colonies) for all positions in the 
reference sequence harboring a C nucleotide outside of CpGs, as well as the number of 
unconverted Cs (corresponds to methylated Cs) and converted Ts (corresponds to 
unmet Cs) in each CpG position. The number of Ts divided by the total number of C + 
Ts defines the bisulfite conversion efficiency.  
 
The data obtained for CpG 26 for cell line SKBR3 and MDA-MB 468 were excluded 
because the CpGs were in the end of the obtained sequences, consequently the read was 
of low quality and the data in the specific positions may be unreliable.  
 
 
Figure 5.3: Methylation pattern in the BRCA1 promoter region in breast cancer cell lines. 
Methylation pattern in BRCA1 promoter determined by PCR amplification from bisulfite treated DNA 
followed by TA cloning and Sanger sequencing. Elements of the BRCA1 promoter region is marked in 
the top of the figure and cell lines are marked to the left. Each CpGs is covered with 20 individual clones 
and the methylation ratio is indicated as a colored scale with completely methylated as red and no 
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The selected cell lines were found to have a varying degree of methylation in the 
analyzed region of the BRCA1 promoter (figure 5.3). Highest frequency of methylated 
CpGs was found in the CpG island region, while the methylation levels in the remaining 
regions were modest. The exception from this pattern was the cell lines UACC-3199 
and HCC38; both these cell lines were extensively methylated throughout most of the 
studied region, but the highest methylation frequency was still observed within the CpG 
island. The cell line BT549 was close to unmethylated in the same region, with only 2 
of the 66 CpGs having some methylation. A low methylation frequency was also 
observed for cell line ZR-75-1. The remaining cell lines had intermediate methylation 
levels, where a clear pattern emerged with more methylation in CpG island relative to 
region A and B. BT549 and HCC38, the cell lines with the lowest and highest 
methylation frequency, respectively, are both triple negative with respect to ER, PR 
and Her2 status. UACC-3199, also found to be extensively methylated are ER and PR 
negative, but Her2 positive. Other cell lines that are ER and PR negative include 
SKBR3, MDA-MB 231 and MDA-MB 468, these were found to have an intermediate 
methylation frequency. As such, the observed methylation patterns did not seem related 
to breast cancer subtype in terms of hormonal receptor status and/or triple negativity.   
 
5.1.2 BRCA1 mRNA expression in breast cancer cell lines 
Experiments for detection of BRCA1 mRNA expression levels were performed to 
assess the effect of methylation status in the BRCA1 promoter region of nine cell lines. 
qPCR was performed to quantify the relative total mRNA levels of BRCA1 WT as well 
as specific assays to quantify the levels of the two transcripts from each of the promoters 
(BRCA1 WT α and BRCA1 WT β). In addition, mRNA potentially expressed from the 
BRCA1 pseudogene were analyzed (BRCA1 pseudo α and BRCA1 pseudo β), as 
described in section 4.18.  
 
To eliminate potential cross reactions between the assays due to sequence similarity, 
the BRCA1 WT a assay was performed using BRCA1 pseudo template cDNA (14 ng) 
and the BRCA1 pseudo a assay was performed with BRCA1 WT a cDNA template (14 
ng). The same cross over experiments were performed for BRCA1 WT b and BRCA1 
pseudo b assays (table 5.1.1). A cut off for mRNA detection levels was set to CP-value 
equal or above 40. All cross-reaction measurements were found to be negative. Taken 
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together, these results indicated that despite the sequence similarities between BRCA1 
WT and pseudo gene, all assays had adequate specificity.  
 
Table 5.1.1: Overview of qPCR BRCA1 WT and pseudo gene cross reactions  
Primer/probe Template (14 ng) CP-value Δ CP-values 
WT a WT a 
26.87 - 
Pseudo a Negative 
Pseudo a Pseudo a 
25.68 19.32 
WT a 45.00 (Negative) 
WT b WT b 
25.71 - 
Pseudo b Negative 
Pseudo b Pseudo b 
30.65 14.35 
WT b 45.00 (Negative) 
 
All data (recorded as CP-values; i.e maximum 2nd derivative point on the reaction 
curves) were converted to relative concentrations by use of an in-run standard curve, 
specific for each assay. Relative concentrations were then adjusted for run-to-run 
variations by a fixed calibrator (pooled cell line cDNA) included on each reaction-plate. 
Finally, the data for each sample were corrected for the corresponding levels of mRNA 
for the ribosomal protein RPLP2. The relative mRNA levels of BRCA1 WT total, 
BRCA1 WT a and BRCA1 WT b for the nine breast cancer cell lines are presented in 
figure 5.4. In general, the vast majority of the BRCA1 mRNA was found to be BRCA1 
WT a compared to a smaller fraction of BRCA1 WT b, extending from 185 fold to 28 
fold (median of 76 fold) higher for BRCA1 WT a than WT b within each cell line 
(figure 5.4 A). Due to major differences, none of the BRCA1 WT b levels are visible in 
the figure 5.4 A. The overall expression levels for BRCA1 WT a of the different cell 
lines were similar to the expression levels of BRCA1 WT total. 
  
Regarding the differences in BRCA1 mRNA expression between the nine breast cancer 
cell lines, a 16-fold difference in BRCA1 WT total mRNA concentration was observed 
between cell line SKBR3 (lowest expression levels) to cell line T-47D (highest 
expression levels). The cell lines with the lowest BRCA1 WT total expression was 
SKBR3, MDA-MB 231 and HCC38, respectively, while the cell lines with the highest 
expression levels were T47D, ZR-75-D and BT549, respectively. When looking at the 
BRCA1 WT experiment, the greatest difference in mRNA levels for BRCA1 WT ɑ was 
observed for cell line MDA-MB 231 compared to cell line T-47D with a 25-fold 
increase for cell line T-47D.  
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Figure 5.4: Relative concentrations of BRCA1 mRNA for nine breast cancer cell lines. mRNA levels 
were measured for BRCA1 WT total, BRCA1 WT a and BRCA1 WT b using LightCycler 480 Probes 
Master with hydrolysis probe assay. Numbers 1-9 correspond to cell lines SKBR3, ZR-75-1, UACC-
3199, BT549, T47D, HCC38, MCF-7, MDA-MB 231 and MDA-MB 468, respectively. The mRNA 
expression levels of BRCA1 WT total (dark blue), BRCA1 WT a (purple) and BRCA1 WT b (red) relative 
to each other (A). BRCA1 WT total, BRCA1 WT a and BRCA1 WT b alone (B).  Relative mRNA 
concentration is plotted against the nine cell lines. All data are corrected by both internal calibrator as 
well as for housekeeping gene RPLP2. Relative mRNA levels were calculated by the use of a specific 
standard curve for each assay. For comparison of data across assays a ΔΔCT-approach was applied, 
where ΔCP-values of respective target genes were first calculated, then these were converted to relative 
concentrations by applying 2 as the efficiency number (Δ concentration between two samples = 2ΔCP), as 
explained in section 4.17.  
 
When comparing relative mRNA levels between two different transcripts (a and b) for 
the nine cell lines, it is evident that the mRNA expression pattern for BRCA1 WT β is 
much lower than BRCA1 WTa (figure 5.4 B). In general, however, the distribution of 
BRCA1 WT β expression among the cell lines were similar to relative levels of BRCA1 
WT a, except for the cell line UACC-3199 which had no detectable mRNA for BRCA1 
WT β transcript and cell line MDA-MB 468, which had more expressed b transcript 
than expected according to a expression. Assessing the association between the levels 
of the two transcripts, a clear trend was observed, however, the data did not reach 
statistical significance (p>0.3), probably due to the low number data points / cell lines 
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Figure 5.5: Correlation between BRCA1 WT a mRNA and BRCA1 WT b mRNA expression levels. 
Relative concentrations were plotted against each other with WT a on x-axis and WT b on y-axis. 
Spearman’s Rho (r) were calculated to assess the rank correlation (r=0.38) (p>0.3).  
 
Regarding BRCA1 pseudo mRNA expression, the qPCR analysis showed some 
expression for BRCA1 pseudo a, however, the detected CP-value for all of these cell 
lines were above 40, and when the assay was repeated, the expressed cell lines did not 
show consistency. According to the sensitivity threshold set for this experiment, the 
qPCR analysis showed no detectable expression of pseudo BRCA1 a nor, pseudo 
BRCA1 β mRNA in this experiment (figure 5.6).  
 
 
Figure 5.6: BRCA1 pseudo a (A) and b qPCR (B) measurements. Detected fluorescent signal was 
plotted against cycles. Each assay was run with a specific standard curve composed of eight 
concentrations. Samples with positive signal had a red color, while negative samples were green. Three 
BRCA1 Pseudo a samples gave positive signal, however all samples had CP-values above 40 (samples 
are indicated by arrows). Master mix and water was included as negative controls.  
 
The BRCA1 WT total qPCR data (figure 5.4) were compared to the methylation pattern 
found for the corresponding breast cancer cell lines (5.3), however, no clear correlation 
could be observed for the overall methylation pattern of the cell lines and the 
corresponding mRNA expressed levels. The cell lines with the most extensive 
methylation, namely UACC-3199 and HCC38, had intermediate to low levels of 
detected mRNA, where HCC38 showed less BRCA1 expression than UACC-3199. 
A B
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However, both cell lines SKBR3 and MDA-MB 231, with intermediate methylation 
frequency, had lower BRCA1 WT mRNA expression than HCC38. The cell line with 
highest mRNA expression levels, T-47D, had similar methylation pattern as the two 
cell lines with the lowest mRNA expression, SKBR3 and MDA-MB 231.  
 
When assessing smaller regions and their association to BRCA1 WT mRNA expression, 
a weak correlation could be found between the methylation of CpGs 22-24 and mRNA 
levels. SKBR3, MDA-MB 231 and HCC38, methylated in CpGs 22, 23-24 and 22-24 
respectively, generally had lower mRNA expression than the unmethylated. Cell lines 
UACC-3199 was also methylated in CpG 22-24 but with a slightly higher mRNA 
expression level. However, the expression level was still lower than the samples that 
have no detected methylation in the same positions. A weak association could also be 
seen for methylation of CpG 56 and BRCA1 WT total mRNA expression, as the cell 
lines harboring some methylation in this position had lower expression levels of BRCA1 
WT total mRNA than cell lines that were unmethylated in the same CpG. However, 
among the cell lines having the lowest WT total mRNA expression (SKBR3 and MDA-
MB 231) only a small percentage of the 20 molecules covered were found to be 
methylated in CpG 56.    
 
Taken together, no correlation is prominent when looking at the overall methylation 
pattern and BRCA1 WT total mRNA expression, however a weak link might be seen 
for smaller regions or individual CpGs and the BRCA1 WT total mRNA expression.   
 
5.1.3 BRCA1 protein expression in breast cancer cell lines 
Western blot analysis was performed to investigate the BRCA1 protein levels in the 
different breast cancer cell lines. For all nine cell lines, a band corresponding to the 
expected size of BRCA1 protein (220 kDa) was detected (figure 5.7). Most of the cell 
lines had a similar expression of BRCA1 protein, except from HCC38 and MDA-MB 
231, which showed approximately 2-fold increased expression, and MCF-7, which had 
close to no detected protein. Several additional bands were observed around 70 kDa, 
possibly due to splice variants, partial degradation or unspecific binding of the 
antibody. The loading control actin (42 kDa) showed similar loading of the nine 
samples.  When comparing the observed expression levels to the detected methylation 
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levels, no clear association could be observed between the BRCA1 promoter 
methylation pattern and BRCA1 protein expression among the cell lines. 
 
Figure 5.7: Western blot analysis of BRCA1 protein expression in nine breast cancer cell lines. 
Protein lysate of the nine cell lines were run on a on a 10% polyacrylamide gel along with molecular size 
ladders PS11 and Precision Plus followed by western blot analysis. The BRCA1 protein (220 kDa) and 
marked with an arrow in the top of the gel picture. Acting (42 kDa) was used as a loading control. The 
ladders are detection by both white light and chemilumeniscence.  
  
5.2 Effect of alterations in the a and b promoter, including site-specific 
methylation and polymorphic variants, on BRCA1 expression 
 
The aim of the second part of this thesis was to investigate how the BRCA1 expression 
levels, as well as ratio between the a and b transcripts was affected by alterations in the 
a and b promoter region of BRCA1. More specifically, CpG site-specific methylation 
as well as two common polymorphisms in BRCA1 promoter region were to be assessed 
by generating and transfecting luciferase reporter constructs with different methylation 
patterns for each of the BRCA1 promoter-pGL4.10[luc2] polymorphism versions and 
analyze the effect on protein expression by bioluminescence assays.  
 
5.2.1 Introduction of site-specific methylation in the BRCA1 promoter to assess 
effect on promoter strength and ratio of  a versus b transcript 
For this purpose, the BRCA1 promoter region (1946 bp) was amplified (section 4.8), 
yielding a PCR product of expected size (figure 5.8 A). The BRCA1 promoter region 
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was subsequently cloned into the luciferase expression vector pGL4.10[luc2] (4242 bp) 
using restriction enzymes as described in section 4.12.  
 
Sequencing of plasmids containing the BRCA1 promoter region from DNA originating 
from pooled blood samples of five healthy donors, showed the presence of two 
construct differing in the polymorphic positions rs71361504 (AAC/-) and rs799905 
(G/C) (figure 5.1 and 5.9). For simplicity, the construct harboring the deletion variant 
of AAC in position rs71361504 and C in position rs799905 were named BRCA1 
promoter-v1.1-pGL4.10[luc2] (or simply just version 1.1). The construct harboring the 
combination of AAC and G in the respective positions were called BRCA1 promoter-
v2.1-pGL4.10[luc2] (or simply just variant 2.1) in the text. Both were to be used as 
template for introduction of site-specific methylation, however, the site-specific 
methylation protocol was first tested on the major allele (most frequent in the 
population) BRCA1 promoter-2.1-pGL4.10[luc2] constructs. 
 
To introduce site-specific methylation in the BRCA1 promoter-2.1-pGL4.10[luc2] 
constructs, the protocol described in methods section 4.20 was followed. The primers 
used harbored methylated cytosines at positions of interest located within the a and b 
promoters (CpG 33, 43-44 and 48-52 - corresponding to the same CpG numbers as in 
the cloning experiment). A critical quality control step during this protocol was 
detection of correct DNA band post T7 exonuclease treatment, for removal of unligated 
DNA. Our data revealed the presence of a weak band of approximately 8000 bp in the 
aliquot from pre-T7 exonuclease treatment (figure 5.8 B). However, no band was 
observed post-exonuclease treatment, most likely due to unsuccessful ligation during 
the combined PCR and ligation reaction.  
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Figure 5.8: PCR amplification of BRCA1 promoter region and introduction of site specific 
methylation into the construct BRCA1 promoter-pGL4.10[luc2]. PCR amplification of BRCA1 
promoter for subsequent cloning into vector pGL4.10[luc2] for generation of the construct BRCA1 
promoter-2.1-pGL4.10[luc2] (A). After the combined PCR-ligation reaction in the first step of the site 
sp methylation protocol, the products were treated with DpnI and T7 exonuclease. Aliquots from pre-
exonuclease and post-exonuclease treatment were run on a 2% agarose gel along with the DNA ladder 
Generuler. Master mix was included as negative control (B).  
 
Several attempts were made to improve the PCR-ligation reaction: modifications that 
were tested include addition of polynucleotide kinase before adding extra ligase after 
the combined PCR-ligation reaction, testing of purification both with and without prior 
separation on gel, reduced purifications steps and reduced exonuclease treatment (down 
to 30 minutes). However, none of these modifications led to successful PCR-ligation 
reaction. The original plan to continue with DnmtI treatment was therefore abandoned, 
and the subsequent steps were never performed. The full focus of this sub-aim was 
shifted to explore the potential differences in BRCA1 promoter strength caused by the 
two polymorphisms detected in the general population.  
 
5.2.2 Effect of SNP variants in the BRCA1 promoter on protein expression 
The original aim was to produce and transfect a repertoire of luciferase reporter 
constructs with different methylation patterns for each of the BRCA1 promoter-
pGL4.10[luc2] polymorphism variants and analyze the effect on protein expression by 
bioluminescence assays. However, as the protocol for introduction of site-specific 
methylation did not succeed, the focused was moved to analyzing the effect of 








were different in two positions; thus, intermediates variants were made by site directed 
mutagenesis (section 4.21) and named variant 1.2 and 2.2 (figure 5.9).  
 
 
Figure 5.9: Schematic presentation of BRCA1 promoter pGL4.10[luc2] SNP version 1.1, 1.2, 2.1 
and 2.2. BRCA1 promoter-pGL4.10[luc2] variant 1.1 and 2.1 were detected by sanger sequencing of 
pooled blood DNA, while variant 1.2 and 2.2 were made by site-directed mutagenesis. The 
polymorphisms rs71361504 and rs799905 were in positions Chr17:43125989-90 and Chr17:43125170, 
respectively, in human genome version 38, corresponding to -598 and +221 relative to transcription start 
site in reference sequence U37574.1 (GeneBank).  
 
The BRCA1 promoter-pGL4.10[luc2] vector constructs containing the different 
polymorphic combinations in the BRCA1 promoter, were transfected into MCF7 cells 
for subsequent bioluminescence measurements. However, before comparing the 
expression levels from the different constructs, the assay was optimized in terms of 
substrate incubation time. Thus, the luciferase signal generated in cells transfected with 
construct BRCA1 promoter-V.2.1-pGL4.10[luc2] (major allele) was measured at 1, 2, 
5, 7 and 10 minutes after addition of substrate. The measurement showed a peak in the 
signal strength after 2 minutes of incubation, and which the following measurements 
showed a steady decrease in the luciferase signal (figure 5.10 A). Based on these results, 
subsequent luciferase assay measurements for the all BRCA1 promoter-pGL4.10[luc2] 
polymorphic-versions were performed after 2 minutes incubation with substrate.  
 
A total of seven luciferase assays were performed for the four BRCA1 promoter-
pGL4.10[luc2] variants 1.1, 1.2, 2.1 and 2.2 as described in methods section 4.20. Each 
sample was measured in six parallels for each experiment, and the measurements were 
normalized according to corresponding GFP measurements. Mean, standard deviations 



















constructs within the six parallels both before and after normalization. Median relative 
standard deviation was found to be 11.35% with a range from 4.48% to 24.50% after 
normalization. Luciferase expression strength were found by calculating a new average 
composed of the mean signal value for each variant in each of the seven experiments 
performed, followed by calculation of standard deviations (figure 5.10 B). Version 2.1, 
which is the major allele in the Caucasian population were set as a reference (100%) 
and the signal strength of the other three variants were calculated accordingly.  
 
 
Figure 5.10: Bioluminescence measurements for BRCA1 promoter SNP variants pGL4.10[luc2] 
1.1, 1.2, 2.1 and 2.2. In order to find the optimal time for measurements of bioluminescence after addition 
of substrate, a bioluminescence assay was performed for the major allele BRCA1 promoter variant 2.1 
measuring the bioluminescence signal 0.5, 2, 5, 7 and 10 min after addition of substrate. The assay show 
a steady decrease in signal over time. For the following assays, the reactions were measured 2 minutes 
after addition of the substrate (A). The luciferase measurements of BRCA1 variant 1.1, 1.2, 2.1 and 2.2. 
All samples were normalized according to co-transfected eGFP, and the calculation are based on six 
parallels in seven assays Version 2.1, the major allele in the Caucasian population, was set as reference 
and the other SNP-versions were calculated accordingly (B).  
 
When assessing the influence of rs799905 and rs71561504 on gene expression, the 
bioluminescence assay for the versions 1.1, 1.2, 2.1, and 2.2 were compared. When 
comparing the two variants of rs799905 (G compared to C), the nucleotide identity in 
the other polymorphic position, rs71561504, was kept identical. As rs71561504 exists 
in two forms (AAC/-), the comparison of C and G in rs799905 was performed both 
with the -/- version and AAC/AAC version of rs71561504. The luciferase expression 
was found to be significantly higher for the construct harboring the C-allele (1.1) versus 
the G-allele in construct variant (1.2) (p=0.0454) (both construct harboring the deleted 
version of rs71561504). The opposite was shown for construct variant 2.1 (G) versus 
variant 2.2 (C), where the G-allele showed significant higher luciferase expression 
compared to the C-allele (p=8.17E-06) (both construct harboring the AAC/AAC 







































variants of the rs71561504 (AAC+ compared to AAC-). The variant without the 
deletion, variant 2.1 (AAC+), had a significantly higher expression than variant 1.2 
(AAC-) (p=0.0092) (both harboring version G of the rs799905). In the next comparison, 
version 1.1, with deletion (AAC-) had significantly higher expression than version 2.2 
(AAC+) (p=0.0012) (both harboring version C of the rs799905)), again showing 
opposing results (figure 5.9 and table 5.2.1). 
 
Notably, version 1.1 (AAC) and 2.1 were the two versions found natural occurring in 
healthy individuals and these two versions yield a similar luciferase expression 
(p=0.6126). Version 1.2 and 2.2 were generated by site-directed mutagenesis, and no 
literature could be found about their existence in the population. Both yielded lower 
luciferase expression levels than the naturally occurring versions, with variant 2.2 
having significantly lower expression signal than variant 1.2 (p = 0.0416). 
 
Table 5.2.1: Effect of polymorphic variants on luciferase activity  
SNP Version rs71361504 rs799905 p-value 
1.1 AAC - C 0.0454 
1.2 AAC - G 
2.1 AAC + G 8.17E-06 
2.2 AAC + C 
1.2 AAC - G 0.0092 
2.1 AAC + G 
1.1 AAC - C 0.0012 
2.2 AAC + C 
1.1 AAC - C 0.6125 
2.1 AAC + G 
1.2 AAC - G 0.0416 
2.2 AAC + C 
 
5.3 Analyzing the effect of long term drug treatment on methylation levels 
in the BRCA1 promoter   
The aim of the third part of the present project was to assess the potential effects of 
long term treatment with olaparib and doxorubicin on the methylation pattern of the 
BRCA1 promoter in breast cancer cell line SKBR3. As such, differences in BRCA1 
methylation were to be assessed as a potential mechanism of resistance to the drugs. 
The cell line SKBR3 was chosen for this experiment, as it has previously been reported 
to be methylated in BRCA1 promoter (Cai et al., 2014). SKBR3 cells were exposed to 
the drugs for an extended period of time at increasing concentrations (figure 4.1), with 
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the lowest doses confirmed to exert an effect by immunofluorescence assay. The effect 
over time on the methylation pattern was analyzed by NGS.   
 
5.3.1 Cell proliferation assay for determination of IC50 for olaparib and 
doxorubicin.  
Before initiating the long term exposure of SKBR3 cells to doxorubicin and olaparib, 
the IC50 was determined for each of the drugs. To estimate IC50 for olaparib (100-1000) 
and doxorubicin (0.02-0.06 µM) in SKBR3 cell line, cell proliferation assay WST-1 
was performed as described in methods. Treatment with both drugs yielded expected 
dose-response curves, enabling estimates of the IC50 points to be made. The IC50 of 
olaparib and doxorubicin was determined to be approximately 260 µM and 0.06 µM 
respectively (figure 5.11).  
 
 
Figure 5.11: Determination of IC50 for the olaparib and doxorubicin in SKBR3 cells. Cells were 
treated with DMSO, olaparib and doxorubicin over a period of 72h before cell proliferation assay WST-
1 was performed. Percentage of living cells were plotted against the drug concentration. IC50 was 
determined to be 260 µM and 0.06 for olaparib and doxorubicin, respectively.  
 
5.3.2 Immunofluorescence assay for detecting dsDNA breaks 
As the aim of this part of the study was to analyze the effect of long time drug exposure, 
the initial drug doses needed to be far below IC50. To verify that the lowest doses chosen 
(1 µM for olaparib and 0.002 µM for doxorubicin) exerted an effect on the cells, 
immunofluorescence assay detecting dsDNA breaks was performed as described in 
methods (section 4.3). SKBR3 cells were treated with the drugs olaparib (1-2 µM) or 
doxorubicin (0.002-0.004 µM) for 48 h. A representative selection of images from the 
experiment is shown in figure 5.12 A. All treatment settings gave positive signals, and 




























a positive signal for staining. Neither of the negative controls showed any FITC signal 
(figure 5.12 B). 
 
The percentages of positive cells were calculated. In the reference sample treated with 
DMSO, 18% cells were found to be positive, compared to 32% and 43%, for 1µM and 
2µM olaparib and 37% and 38% for 0.002 µM and 0.004 µM doxorubicin, respectively 
(figure 5.12 C). Significantly higher number of dsDNA breaks in were found in SKBR3 
cells treated with 1 and 2 µM olaparib as well as a 0.002 and 0.004 µM doxorubicin 
compared to cells treated with reference (DMSO) (p<0.001). These findings showed 
that the lower doses of both drugs, 0.002 µM doxorubicin, and 1 µM olaparib could be 
used as initial drug concentrations for long-term treatment of SKBR3 as they both exert 
an effect on the DNA.  
 
Figure 5.12: Immunofluorescence assay for detecting dsDNA breaks in SKBR3. 
Immunofluorescence assay was performed on SKBR3 cells treated with olaparib (1-2 µM) and 
doxorubicin (0.002-0.004 µM) to detect an effect of the drugs at the specific concentrations. DMSO was 
included as a reference. First column show DAPI staining of the nucleus, FITC staining in the second 
column and the merged pictures in column three (A). Treated cells incubated with primary antibody 
(1AB) only or secondary antibody (2AB) only were included in the assay to show the specificity of the 
antibodies (B). Percentage positive cells were calculated, followed by estimation of the average and 
standard deviation of three parallel experiments. All treatments were calculated to be significantly higher 
than the DMSO control (p< 0.001) (C).  
 
5.3.3 Mycoplasma testing of doxorubicin and olaparib treated SKBR3 cells 
Due to the long duration of the drug treatment experiment, mycoplasma test was 
performed on medium from the initial and final harvesting for both drugs (section 




experiment line, which led to four treatment settings (olaparib experiment, olaparib 
backup, doxorubicin experiment and doxorubicin backup), as well as the control 
treatment (DMSO). All treatment settings were tested. As expected, the positive 
controls show a band between 267-277 bp, and the negative control show only the 
expected band for the internal control of 191 bp (figure 5.13). None of the samples from 
the SKBR3 harvesting tested positive for mycoplasma contamination.  
 
Figure 5.13: Mycoplasma test of SKBR3 cells. Medium harvested from SKBR3 cell cultures were 
tested for mycoplasma by using Venor GeM Mycoplasma Detection Kit. Medium were collected at the 
initial harvesting (no drug) as well as for the final harvesting of each drug; DMSO, olaparib (Olap) and 
doxorubicin (Dox) from both the experiment line and the backup line were tested. Internal control (191 
bp) was added to each sample. Postive (DNA fragment of Mycoplasma orale genome) and negative 
control (mastermix) were run in parallel. The samples were run on a 2% agarose gel with jX174-HaeIII 
digest as molecular marker.  
 
5.3.4 STR profiling of SKBR3 cells from long term experiment 
In addition to the mycoplasma test, the long term nature of this experiment required 
validation of the cell lines identity both before initiation of drug treatment and after 
completion of the entire treatment period; the latter in order to detect any potential 
cross-contamination with other cells during the experiment. The cell line SKBR3 was 
therefore tested for correct identity by STR Profiling (DNA “fingerprinting”; section 
4.1.5). Samples corresponding to the first harvest, containing no drug, as well as the 
final harvest for all treatment settings were STR profiled. All samples from first and 
last harvesting for both drugs (experiment and backup line), as well as the DMSO 
control were found to have a STR profile matching the STR profile of SKBR3 provided 




















Amelogenin X * X X X X X X 
CSF1PO 12 12 12 12 12 12 12 
D13S317 11, 12 11, 12 11, 12 11, 12 11, 12 11, 12 11, 12 
D16S539 9 9 9 9 9 9 9 
D5S818 9, 12 9, 12 9, 12 9, 12 9, 12 9, 12 9, 12 
D7S820 9, 12 9, 12 9, 12 9, 12 9, 12 9, 12 9, 12 
THO1 8, 9 8, 9 8, 9 8, 9 8, 9 8, 9 8, 9 
TPOX 8, 11 8, 11 8, 11 8, 11 8, 11 8, 11 8, 11 
vWA 17 17 17 17 17 17 17 
* X refers to the female X chromosome 
 
5.3.5 BRCA1 promoter methylation by methylation specific NGS 
Long term drug treatment of the cell line SKBR3 was performed to assess potential 
alterations in the methylation pattern in BRCA1 promoter region to further link this to 
drug resistance. SKBR3 cells were treated with increasing concentrations of the drugs 
olaparib (1-8 µM) and doxorubicin (0.002-0.012 µM) for a period of 11-13 weeks as 
described in methods, section 4.1.3. Multiple samples from this experiment were 
subjected to detailed methylation analyses by massive parallel sequencing (NGS) of the 
promoter regions of 283 tumor suppressor genes on bisulfite converted DNA. The 
harvesting time-points for the samples selected for NGS analysis are given in table 5.3.2 
and figure 4.1. 
 











0 x x x x x 
3 x x x x x 
6 x x x   
8 x   x x 
11 x  x   
13 x x  x x 
 
Control samples treated with DMSO were selected for corresponding time points for 
every selected olaparib or doxorubicin treated sample. A summary of the results of 
methylation specific massive parallel sequencing (described in section 4.23) is provided 
in Appendix 1 (table A.2). A series of parameters, used to ensure high quality data, 
were extracted from the sequencing run. The combined Watson and Crick duplication 
percentage (data from both original strands) varied from 2.53% to 7.06%, except for 
the doxorubicin experiment sample harvested in week three (referred to as Dox-week 
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3), which had a duplication percentage of 26.68. The mean capture target coverage 
ranged from 122.69x to 279.35x, except for sample Dox-week 3, which had a mean 
capture target coverage of 53.04x. BRCA1 was the focus for this thesis, and only CpGs 
in the BRCA1 promoter were studied. Mean coverage for CpGs of interest within the 
BRCA1 promoter ranged from 149.21x to 27.42x, with an average of 84.92x. All 
samples except Dox-week 3 had a mean coverage above 60x. The bisulfite conversion 
efficiency (C to T) of the internal Lambda DNA control were found to be on average 
99.45% (range 99.17% - 99.57%) in the analyzed samples. All in all, these measures 
indicated sequencing data of high quality and allowed further biological interpretations 
to be made. 
 
For each sample, the methylation frequency for 66 CpGs located in the BRCA1 
promoter region were extracted from the NGS data, corresponding to the same CpG’s 
analyzed in the plasmid bisulfite sequencing experiment described in section 5.1.1. A 
heat map was constructed, showing the methylation frequency for the 66 CpGs in the 
samples corresponding to SKBR3 treated with DMSO, doxorubicin experimental and 
backup line as well as olaparib experimental and backup line (table 5.3.2, figure 5.14 
A). In general, CpG 1-15 located in the CpG Island were mainly methylated, while the 
rest of the CpGs were largely unmethylated. The findings show only small differences 
between first and final harvesting observed for any of the experimental or backup lines 
when comparing to the DMSO treated control samples. Methylation levels seem to be 
decreasing slightly over time for all samples in the CpG Island region, but this also 
includes the DMSO control samples. Thus, the overall impression is that no major 
differences can be detected, while the minor changes observed are not caused by 
doxorubicin or olaparib.  
 
Further, calculating ratios of methylation levels in individual CpGs (1-15) in the last 
time point versus time point zero, showed that most of the individual CpGs were in 
general demethylated over time, for all treatments including the DMSO control sample 
(figure 5.14 B). Thus, the potential differences do not seem to be related to the drug 
treatments. Apart from the CpGs within the CpG island, the rest of the promoter was 
largely unmethylated. In total, a small decrease in methylation of some CpG with the 
CpG Island was observed over time when treating with doxorubicin and olaparib, 
however, a clear effect compared to the DMSO treated sample was lacking.  
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Figure 5.14: Overview of methylation pattern in SKBR3 cells treated with olaparib and 
doxorubicin detected by NGS. The breast cancer cell line SKBR3 was treated with olaparib and 
doxorubicin over a time period of 11-13 week. DMSO was included as a reference and harvested at time 
points equal to the harvesting of drug treated samples. The drug treated samples were split in one 
experiment line and one backup line for each of the two drug; doxorubicin experiment line (0.002-0.012 
µM), doxorubicin backup line (0.002-0.008 µM), olaparib experiment line (1-8 µM) and olaparib backup 
line (1-4 µM). Samples were harvested and deep sequenced. A) Harvesting time points for the specific 
samples are indicated to the left in the figure. Methylation frequency of BRCA1 promoter were detected 
by use of Roche NimbleGen SecCap Epi Enrichment systems in combination with custom made probe 
panel. CpG 1-66 and the corresponding position within the BRCA1 promoter region is listed in the top 
of the figure. Methylation frequency is presented in a range from one to zero, where more methylated 
samples have a darker red color. Samples with coverage below 10x were excluded from the data and are 
marked as gray shaded squares in the figure. B) The change in methylation over time for each of the 5 
treatment lines was calculated by dividing the methylation frequency for the last harvesting (Tlast) by the 

























Meth. Freq. 1 0
* CpG with coverage <10 are excluded and marked with gray shading
CpG Island α promoter Exon 1a β-promoter
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6 Discussion 
The interplay between cancer and epigenetics raises a multitude of complex questions 
that researchers all over the world are trying to address. The connection between breast 
cancer, BRCA1, and methylation is only one topic on an endless list of matters needed 
to be answered to be able to get a deeper understanding of the cancer disease. Both 
BRCA1 and methylation are topics that have been extensively studied, separately and 
in combination, however, a lot of uncertainties are associated with both themes, and a 
great deal of research remains. The background for studying methylation in the BRCA1 
promoter is based on the knowledge of the severe breast cancer risk associated with 
germline BRCA1 mutations as well as the low BRCA1-mutational rate found in sporadic 
breast cancer even though the mutational profiles can display BRCAness. Furthermore, 
with drug resistance as a major challenge in cancer treatment, as well as an increasing 
interest in the PARP-inhibitor and its potential to be used for all cancers showing 
deficient DSB-repair, it is of great interest to assess methylation as a possible 
mechanism for drug resistance with treatment of both the PARP-inhibitor olaparib and 
the chemotherapy doxorubicin. In this study, we aimed to increase the understanding 
of the biological role of BRCA1 promoter methylation in breast cancer, by addressing 
the subject from several angles; 1) Analysis of correlation between methylation in 
BRCA1 promoter and BRCA1 mRNA and protein expression in breast cancer cell lines. 
2) Investigate the potential effects of alterations in the BRCA1 promoter region, 
including methylation of specific CpGs as well as polymorphism variants, on BRCA1 
promoter strength and ratio between a and b transcripts. 3) Analyze the effect of long 
term drug treatment on methylation levels in the BRCA1 promoter.  
 
6.1 BRCA1 promoter methylation pattern linkage to mRNA and protein 
expression 
In the first part of this study, we wanted to assess the potential links between DNA 
methylation in the BRCA1 promoter, RNA and protein expression. The results revealed 
a large variability in methylation and expression of both RNA and protein levels in a 
panel of breast cancer cell lines. However, only weak associations could be found 
between the methylation pattern in the BRCA1 and the corresponding mRNA levels, 
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while no associations between methylation pattern and BRCA1 protein expression were 
observed. 
 
The 66 CpGs analyzed in this study were distributed between nucleotides 1052 
upstream to 302 downstream of BRCA1 transcription start site, covered both the a and 
the b promoters, as well as a CpG Island located further upstream within the BRCA1 
promoter region. The highest frequency of methylation was observed in the CpG Island 
for all nine cell lines, which may be expected, considering what is known about 
hypermethylation of CpG Islands and silencing of tumor suppressor genes such as 
BRCA1 in breast cancer (Hasan et al., 2013, Hosny et al., 2016). A considerable 
variation in the methylation frequency between the cell lines were found; the cell lines 
UACC-3199 and HCC38 were highly methylated in the whole region studied, while 
the cell lines BT549 and ZR-75-1 were found to be close to unmethylated in the same 
region. None of the CpG-positions stood out as completely methylated or unmethylated 
when comparing all cell lines, thus revealing a highly heterogeneous methylation 
pattern within the BRCA1 region, which is in line with previous descriptions (Wilcox 
et al., 2005, Zhang and Long, 2015, Hansmann et al., 2012). 
 
The qPCR measurements of BRCA1 mRNA in the breast cancer cell line panel revealed 
large differences in the expression levels of BRCA1 WT a and BRCA1 WT b, with the 
expression levels of the a-transcript being higher than the b-transcript in all cell lines 
studied. These findings are consistent with previous studies that report the relative 
levels of BRCA1 WT a to be 6-150 times higher than BRCA1 WT b in tumor tissue and 
cell lines (Xu et al., 1997, Fernandes et al., 2014). All cell lines, except UACC-3199, 
expressed the b transcript. In general, this finding is in line with previous findings 
indicating that the b transcript is only expressed in malignant cells, since all cell lines 
are derived from breast carcinomas (Sobczak and Krzyzosiak, 2002, Xu et al., 1995). 
Furthermore, when comparing relative mRNA expression of BRCA1 WT a to BRCA1 
WT b for each cell line, the expression pattern between the two transcripts seem to be 
following each other, except for cell line UACC-3199 for which no BRCA1 WT b 
mRNA transcript was detected. The correlation for most of the cell lines looks to be 
strong when the values are plotted in a graph, however, the values did not reach 
statistical significance, possibly due to low number of observations (figure 5.5). This 
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suggest that the regulation of a and b not are completely independent, but that the two 
transcripts might be co-regulated. According to our knowledge, this is a novel finding, 
not described in existing literature. Moreover, transcription of the pseudo gene, detected 
by both qPCR and luciferase assay, has been described by one group (Pettigrew et al., 
2010). However, none of the cell lines analyzed in this study showed BRCA1 pseudo a 
nor b mRNA levels within the detectable range when measured by qPCR analysis.  
 
The findings of a minor association between methylation pattern and BRCA1 WT total 
mRNA expression in this study were only partially in line with the data in existing 
literature. As mentioned above, cell lines UACC-3199 and HCC38 were found to be 
extensively methylated over the whole studied region, which according to the literature 
is associated with lower gene expression (Hasan et al., 2013), and indeed this was the 
findings for the cell line HCC38. However, cell line UACC-3199 had intermediate 
expressed mRNA levels, not consistent with what would be expected. When looking at 
the opposite end of the scale, the cell lines BT549 and ZR-75-1 displayed low degree 
of methylation, expression level would be expected to be higher than for the methylated 
cell lines, and in fact, both cell lines had higher BRCA1 WT total mRNA expression 
levels compared to all but one cell line. Cell line T-47D, which was found to be 
intermediate methylated, had the highest mRNA expression for both BRCA1 WT a and 
b.  
 
Smaller regions and individual CpGs were further studied to connect methylation in 
transcription factor binding sites to expression levels (relative positions can be found 
in figure 5.1). However, no obvious correlation was found even though several 
transcription factor binding sites have previously been reported to be affected by 
methylation in the promoter region of BRCA1 (Choudhury et al., 2016, Shin et al., 
2013). If the methylation frequency is not taken into consideration, but simply 
determining if methylation is present or not, then methylation of CpGs 22-24 might be 
linked to BRCA1 WT total mRNA levels. No transcription factor binding sites are 
described in the literature to be in immediately proximity to the position of these CpG 
sites, however, as the DNA is flexible, these sites have the potential to affect 
transcription factors binding to sites more distantly away from their own positions. 
Moreover, even though only a low frequency of methylation was found, methylation at 
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CpG 56 was consistent with lower BRCA1 WT total mRNA expression. This CpG is 
positioned close to an AP-1 binding site involved in BRCA1 regulation by estrogen 
trough a non-classical activation pathway (figure 5.1). Other transcription factors 
previously identified to be affected by methylation in BRCA1 include Sp1, Egr-1 CTCF, 
E2F1 and E2F6 and CREB (Choudhury et al., 2016, Xu et al., 2010, Debora et al., 
1998), but a direct link to any of these was not found in this study. These findings could 
be explained by variations between the cell lines, other than methylation status, such as 
varying expression levels of different transcription factors in the specific cell lines. No 
correlation was found between the receptor status/breast cancer sub-class and 
methylation pattern. Usually it is triple negative breast cancer that is associated with 
BRCAness, however, no correlation was found here.  
 
While the BRCA1 WT a transcript is found in both normal mammary tissue and cancer 
tissue, the b transcript is only found to be expressed in breast cancer tissue and to a 
much lower extent (Xu et al., 1995). Methylation could potentially be involved in the 
mechanism switching the use from a- to the b-promoter. If methylation were to be 
involved in this switch, one might expect a setting where the a promoter was 
hypermethylated and the b.promoter unmethylated, but this was not the case. No 
prominent pattern in the methylation of the cell lines analyzed in this study support 
such a mechanism. Thus, no support for this hypothesis was found in this study.  
 
For the cell line UACC-3199, the measured levels of BRCA1 WT a mRNA were higher 
than BRCA1 WT total, which is not logical. However, UACC-3199 is also the cell line 
with the highest standard deviation, and these uncertainties in the measurements might 
have affected the final concentrations measured. It is also important to stress that the 
relative calculations between qPCR assays are based on a theoretical approach, 
assuming perfect reaction efficacy, while the reaction efficacy may be slightly different 
between the assays.  
 
With respect to the BRCA1 protein expression analysis, the cell lines that stand out are 
HCC38, MDA-MB 231 and MCF-7, where HCC38 and MDA-MB 231 show the 
highest expression and MCF-7 show the lowest expression of protein compared to the 
rest of the cell lines in the in the cell line panel studied. The cell line MDA-MB 231 
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had intermediate methylation frequency, while cell lines HCC38 and MCF-7 were 
found to have high and low methylation frequencies, respectively. The fact that HCC38 
has high frequency of methylation as well as high protein expression, and MCF-7 has 
relatively low degree of methylation and low protein expression is directly opposite of 
what would be expected in a simple model where epigenetic regulation is directly 
linked to expression (Wu et al., 2016, Scott et al., 2016). HCC38 and MDA-MB 231 
also have low mRNA expression levels, again, making it more difficult to link the 
increase in protein of these samples to the methylation pattern and mRNA levels, as 
well as to the data obtained for the rest of the breast cancer cell lines. Similarly, MCF7, 
has a low degree of methylation, medium high mRNA expression, but close to no 
protein expression. While this may seem counter-intuitive, there are several possible 
explanations including differences in the transcription- and translation factors 
expressed in the various cell lines, as well as differences in factors affecting mRNA 
stability and protein degradation. In sum, there might be a link between methylation 
and mRNA expression, but the two extremes of methylation frequency were not clearly 
reflected in the mRNA expression levels.  
 
6.1.1 Methodical considerations for the experiments performed to link 
methylation frequency to expression data 
A total of 20 successfully sequenced colonies were obtained for each cell line, which 
should be sufficient to establish the biological basis of the methylation pattern in the 
BRCA1 promoter the in samples. Additionally, the samples are of low heterozygosity, 
which support the need of fewer numbers of individual molecules analyzed. The 
bisulfite conversion efficiency was found to be 95.63%, which is above the threshold 
(99.5%) set by the manufacturer of the kit. Furthermore, even though the aim of this 
part of the study was to search for potential links between DNA methylation, RNA and 
protein in cancer cell lines, it would have been very useful to have included a benign 
breast cell line, like the MCF10A, as a control sample, to be able to compare the 
methylation pattern, mRNA and protein expression from the cell lines harvested from 
breast cancer patients, with a non-cancer setting. However, even if the MCF10A cell 
line arise from normal breast tissue, the cells are immortalized and it is therefore 
uncertain whether they truly reflect normal breast tissue. Furthermore, western blot 
analysis without ghost bands and darker regions should ideally be obtained, but limiting 
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sample material of cell line UACC-3199 did not permit a new SDS-PAGE run to be 
performed. Aliquots of this cell line were collected and frozen in liquid nitrogen and 
could have thawed for propagation and harvesting for sample material, but as the cell 
line was extremely difficult to grow, this was not prioritized.  
 
6.2 Modification of the site-specific methylation protocol 
One of the sub aims of this study was to introduce methylation in specific positions 
within the BRCA1 promoter and investigate if this would affect the promoter strength 
and ratio of a and b transcript by performing luciferase assay. However, the selected 
protocol for introduction of site-specific methylation turned out to be challenging to 
perform, and constructs with methylation in the wanted positions were never 
successfully obtained. The protocol was initially performed as described in the article 
“Site-specific reporter construct for functional analysis of DNA methylation” by Han 
and colleagues (Han et al., 2013), and additional information was obtained by personal 
correspondence with the author. However, agarose gel analysis of product after the 
second step of the protocol, which involved digestion of parental and un-ligated DNA, 
showed the presence of DNA before exonuclease treatment, but not after. These results 
indicated a problem with the ligation of the PCR product in the first step in the protocol. 
 
Several modifications were tried to optimize the combined PCR and ligation reaction, 
including excess of ligase in the reaction mixture, two types of ligases along with 
polynucleotide kinase, as well as addition of ligase directly after the PCR-program was 
finished. DNA loss was minimized by reducing the numbers of clean up steps and 
different purification protocols were attempted, for selection of the protocol with the 
highest yield. Furthermore, the duration of exonuclease treatment was reduced from 
overnight to only 30 minutes. Nevertheless, none of these steps resulted in a visible 
product when analyzing post-exonuclease samples on agarose gel. The Taq DNA 
ligase, used both in the experiments for this thesis and in the experiments described in 
the original paper, is active at temperatures 45-65°C according to the manufacturer. 
However, PCR cycling includes much higher temperatures, and the enzyme would need 
to tolerate temperatures up to 98°C. Han and colleagues do not mention this in their 
description of the method, and seem to have got the reaction to work satisfactory, but 
we consider this to be a likely cause for the failure of the method.  
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6.3 Polymorphic variants affecting the expression of BRCA1 assessed by 
Luciferase assay 
Due to unsuccessful attempts to introduce site specific methylation, the focus was 
shifted to only assessing the effect of the polymorphisms rs71361504 and rs799905 in 
the BRCA1 promoter on expression. The naturally existing variants, detected in a 
pooled blood sample from five healthy individuals, differed in two positions, thus 
intermediate variants were made to be able to determine the effect of each position 
separately. BRCA1 promoter-pGL4.10[luc2] variant 1.1 and 2.1 exist naturally and 
were found to have equal expression of luciferase reporter vector, while variant 1.2 and 
2.2, both generated in the lab, showed significantly lower luciferase expression. The 
two naturally occurring variants seem to counterbalance the effect of each other, 
resulting in an equal BRCA1 expression. SNP rs799905 lies with in a CpG, if the G-
allele is present, then a possible methylation site is deleted (figure 5.1) (Hansmann et 
al., 2012). This SNP is in addition located in close proximity to several TF binding 
sites, and thus, has the potential to affect transcription depending on whether the 
methylation site is present or not, as well as if it is methylated or not. Possible TF 
binding sites that can be affected by this SNP are SP1, AP1 and CREB, some of which 
is known to be affected by methylation (Choudhury et al., 2016).  
 
Polymorphism rs71361504 is described in relation to endometriosis, but not in relation 
to breast cancer or methylation (Govatati et al., 2015). Furthermore, current literature 
has described transcription factor binding sites in the a and b promoter, while this 
polymorphism is located closer to the CpG Island, thus little was found regarding 
possible effects on transcription by the presence/absence of the trinucleotides AAC. 
However, when searching in the transcription factor binding site database JASPAR, 
three additional TF binding sites were found when the trinucleotides AAC were present 
in the sequence; namely SRY, SOX10 and NFIC. The existence of variants 1.2 and 2.2 
in the population is not described in the literature. If these versions do not exist, a 
possible explanation could be that when these polymorphic variant combinations are 
present in the genome, the expression of BRCA1 is too low, resulting in a non-viable 
offspring. However, if the version does exist, more knowledge would be needed to 
potentially link these to disease risk.  
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6.3.1 Methodical considerations for the assessment of polymorphic variants 
In the original protocol for luciferase assay Dual-Glo® Luciferase Assay System, both 
firefly and Renilla luciferase luminescence signals are measured. However, in this 
study, eGFP was chosen for normalization as previous experiments in the lab have 
shown bleed-trough of the Renilla signal. 
 
MCF7 was selected for this assay as transfection protocols were already established for 
this cell line in the lab. The strength of the findings would have increased if the 
experiments were repeated for several additional cell lines, however due to time 
limitations this was not feasible.  
 
6.4 Long term treatment of SKBR3 with doxorubicin and olaparib for 
methylation status assessment 
The aim of the third section of the presented work was to investigate the effect of long 
term treatment with olaparib and doxorubicin on the methylation status in the BRCA1 
promoter of the breast cancer cell line SKBR3. It was of interest to assess whether long 
term treatment with olaparib or doxorubicin, pushing the cell culture towards drug 
resistance, could potentially cause demethylation and subsequent upregulation of 
BRCA1, as a possible mechanism of drug resistance.  
 
NGS analysis, performed on the selected harvests from the long-term treatment 
experiment, showed only minor effects on the BRCA1 methylation pattern. A small 
decrease in methylation was detected over time, however, this slight trend was also 
observed for the control (DMSO) sample. Calculations of the ratio for the last 
harvesting versus the harvesting at time point zero show that the demethylation pattern 
of both backup lines look very similar to the DMSO control, while the experiment lines 
for both drugs showed a slightly more prominent demethylation pattern. As such, the 
overall impression from these experiments is that the minor changes observed are 
linked to general development of the cell cultures rather than drug specific effects. 
DMSO is also slightly toxic to the cells, and can potentially affect the methylation 
pattern over time.  
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Even though only a small difference is seen for experiment lines compared to backup 
lines and DMSO, it might be possible that this trend could be more evident if the cells 
had been treated with a higher dose and/or for a longer period of time. The first increase 
in concentration was done only after four weeks of incubation with the initial drug 
doses. The drug concentrations were then increased gradually until maximum dose 
were reached, detected when proliferation drastically decreased. A more slow and 
steady increase, as well as treatment over an even longer period could possibly have 
allowed a higher max concentration, and maybe, a more visible effect could have been 
detected. However, in this experiment, the differences are too small to suggest that the 
long term drug treatment causes demethylation.  
 
SKBR3 was chosen as the model cell line for this experiment because it has previously 
been reported to be methylated in the promoter region of BRCA1 (Cai et al., 2014). 
Ideally, the selection of an appropriate cell line should have been based on own 
findings. However, due to time limitations for the project, a cell line had to be chosen 
based on literature search, prior to own methylation-screen of cell lines. When the 
methylation data from the cloning experiment with the nine breast cancer cell lines were 
obtained, SKBR3 were found to be methylated only in the CpG Island region of the 
promoter. The relatively low frequency of methylation in this cell line in the first place, 
limited the observations to the CpG Island and approximately 20 CpG sites. This is a 
potential drawback of the experimental set up. If this methylation data (figure 5.2) had 
been obtained prior to starting the long-term experiment, the cell line UACC-3199 or 
HCC38 may have been used instead of SKBR3, as these were methylated in the whole 
region studied.  
 
6.4.1 Methodical considerations for the long term cell culture experiments 
The results of the NGS analysis performed by the use of Roche NimbleGen Seq Cap 
Epi Enrichment Systems with a custom-made probe design showed a bisulfite 
conversion rate of 99.45%. Although this is just below what is usually recommended 
as standard conversion rate (99.5%), it should not cause any ambiguity in the data. 
When comparing the methylation pattern of cell line SKBR3 for the cloning experiment 
and the NGS experiment (untreated sample), the two different approaches give the same 
results, strengthening the data of both experiments. 
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The duplication rate was below 10% for all samples, except one. This may seem like a 
high duplication rate compared to sequencing of unmodified DNA. However, for 
bisulfite converted samples, such numbers still indicate libraries of high quality. The 
sequencing data for the BRCA1 promoter showed that the average capture target 
coverage for all samples, except one, were above 60x. In the ideal setting, one may 
always wish for a higher coverage, but the amount of data generated in this study is a 
compromise between the number of reads per nucleotide, size of target region and the 
time/cost issues. It is arguable that 60x is adequate coverage for this project since the 
data are collected from one cell line (low heterozygosity of the sample) and the aim 
was to investigate changes over time. On the other hand, the study focuses on 
methylation frequency, meaning that the results will be detected as continuous values 
and not merely negative, 50% or positive. To re-run the sample libraries to increase the 
resolution could be a future perspective.  
 
Compared to all other samples, the sample named “Dox, week 3”, had a much lower 
coverage and higher duplication rate, despite using recommended amount of input 
DNA in the library preparation. The sample was run twice, but the same results were 
obtained in both cases. The identical index (named 002) was used in both library 
preparations, in order to be able to combine the reads from the two runs in the 
bioinformatical pipeline after sequencing. When measuring the concentration of index 
sample 002 solution, it turned out to be much lower compared to other randomly 
selected indexes shown to provide adequate sequencing results. The low DNA 
concentration of this index most likely explains the low quality parameters observed 
for “Dox, week 3”. Further, even though this sample does not meet all the quality 
criteria, the final heat map does not seem be affected by the lowered confidence of the 
results that this sample is based on. 
 
In the context of methylation, mapping of the resulting reads after NGS is extra 
challenging because a target region could be fully methylated, partly methylated or 
unmethylated. An exponential relationship exists between the number of methylation 
sites and the theoretical possible combinations of methylations patterns. In addition, 
after the bisulphite conversion of the DNA the upper and lower strand are no longer 
complementary, this doubles the size of the genome and makes the mapping even more 
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complex and time consuming. The program Bismap used is this experiment, is among 
most accurate program in current use (Xi and Li, 2009). 
 
It is important to keep in mind that several techniques excite for detection of 
methylation, as described in the inductions (section 1.4.2 and 1.4.3each with its own 
strength and weaknesses, and comparison of the resulting data can therefore be 
challenging. This includes methylation data obtained both in this experiment, as well 
as date data found in existing literature.  
 
6.5 Conclusion 
Being aware of the significant number of people that are affected by breast cancer 
worldwide, and in recognizing the huge effect epigenetics can have in disease 
development, it is of great interest to increase the understanding of BRCA1 promoter 
methylation. This study aimed to investigate the effect of CpG methylation and 
polymorphic variants, in the promoter of BRCA1, on BRCA1 expression, as well as the 
effect of long term drug treatment on methylation levels in the BRCA1 promoter.  
 
In this study, only a weak correlation could be found between the BRCA1 methylation 
pattern and BRCA1 mRNA expression, and no correlation was found between the 
methylation pattern and expressed protein, or between mRNA levels and protein 
expression. Furthermore, analysis of construct harboring site-specific methylation was 
never performed successfully, but the effects of two polymorphic variants rs71361504 
and rs799905 were analyzed by luciferase assay. The two naturally occurring versions 
differing in two positions counterbalanced the effect of each other, both showing equal 
levels of BRCA1 expression as measured by luciferase reporter construct. The two 
intermediate versions, generated in the lab, had significantly lower BRCA1 expression. 
To our knowledge, these are not known to existing naturally. Finally, long term drug 
treatment was not linked to demethylation of the promoter region of BRCA1, and thus 
demethylation could not found to associated to the cells ability to survive drug 
treatment in the experiment setup tested in this study. 
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6.6 Future perspectives 
Although BRCA1 is one of the best characterized tumor suppressor genes, the vast 
majority of research efforts has been focused on mutations and hereditability of 
mutations in the gene. Much remains unknown regarding other mechanisms of BRCA1 
inactivation. As such, further research on BRCA1 methylation is highly warranted, 
together with research on other potential inactivation mechanisms, such as 
translocations of the gene, deregulation of BRCA1, affecting microRNA etc. 
 
Regarding the specific experiments performed in this thesis, there are several lines of 
future work that could be followed; the experiments performed in this study comparing 
BRCA1 promoter methylation patterns to BRCA1 expression showed that there might 
be a link between methylation of some CpGs and mRNA expression, but no clear 
relationship was observed in the chosen panel of breast cancer cell lines. A larger study 
including patient samples and healthy controls would be of interest to get a better 
understanding of which methylation sites are of high importance for mRNA (and 
protein) expression. In a potentially extended study, it would be of interest to include 
both normal tissue of relevance, and biopsy samples from breast or ovarian cancer 
patients (the two cancer forms strongest linked to BRCA1 deficiency). Furthermore, it 
would be interesting to assess the degradation rate of the a and b transcripts by 
performing stability assays. This could be performed by addition of a transcription 
blockage and subsequent performance of qPCR measurements at various time points. 
 
Studies based on site specific methylated construct is a very attractive model for 
studying of the impact of BRCA1 promoter methylation. Therefore, in the future, more 
efforts should be put into making the site-specific methylation protocol to work for this 
promoter. A tempting next step would be to search for a more thermostable ligase 
known to withstand PCR conditions. Another solution could be to try alternative 
methods to generate vectors with site-specific methylation, including methods that are 
mentioned in the article form Han et al, for instance one protocol that used siRNA from 
yeast and plants. However, according to Han and collogues, these methods have lower 
precision and are more time consuming (Han et al., 2013). Recently the CRISPR/Cas9 
method had been modified to be able to add or remove methyl groups at specific 
positions in the DNA (Liu et al., 2016). This could be an exciting approach worth trying, 
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since it would provide a model system where BRCA1 may be expressed at levels close 
to the physiological ones, and one would not need to rely on transfections and 
overexpression experiments. Regarding the polymorphisms studied, only two of the 
four combinations were known to occur naturally, while the two others were made in 
the lab. If the two latter exist in nature, it would be of great interest to assess their 
function further in a high number of human samples and to test the correlation between 
these polymorphic variants and cancer risk.  
 
The long term experiment did not show a strong link between treatment with olaparib 
or doxorubicin and demethylation of the BRCA1 promoter region. In a potential new 
experiment, it would be interesting to use several additional cell lines, all with higher 
degree of methylation as well as a more empirical reasoned treatment plan and 
potentially increased drug doses. A goal would be to cover as much of the BRCA1 
promoter region as possible, as well as covering other regions potentially involved in 
BRCA1 regulation. Additionally, the analysis could be designed to include other genes 
involved in HR repair. Moreover, an overview of methylation position and frequency 
from tumor material of patients that have undergone cancer treatment would be of great 
interest to select for CpGs of high impact, and potentially connect these to change in 
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